 
 Title: Vitamin C Infusion for Treatment in Sepsis Induced Acute Lung Injury (CITRIS -ALI) 
 
PI: Alpha Berry Fowler , MD 
 
NCT #: NCT0210697 5 
 
Unique Protocol ID: HM20000917  
 
Document a pproval date: February 20, 2017 
 
Document Type: Protocol and SAP 
 
 
 
 
CITRIS Protocol Version  9 
 1  
 
 
  
 
Vitamin C Infusion for TReatment In Sepsis Associated Acute Lung Injury  
 
CITRIS-ALI   
Protocol Version 9  
 
   
 
Name  Role  Email  Voice/Pager   
 
Alpha Fowler, III, MD  
 Investigator alpha.fowler@vcuhealth.org 804.519.4369  (c) 
Jonathon D. Truwit, MD Investigator Jonathon.truwit@froedtert.com 434.982.3500.4004  
434-243-7088 
434.227.1663   (p) 
(o) 
(c) 
 
R. Duncan Hite, MD  
 Investigator hited@ccf.org 216.445.3098 
216.386.2099  (o) (c) 
 
Chris DeWilde, MSN, 
RN, CCRC, TCN -A  
Lead Research 
Coordinator  christine.dewilde@vcuhealth.org  804.628.5710 
804.519.0022 (o) (c) 
 
Anna Priday   
Lead 
Regulatory 
Coordinator  anna.priday@vcuhealth.org 804.628.9612 804.221.9258 (o) (c) 
  
 
  
 
CITRIS Protocol Version  9 
 2 ABBREVIATIONS  ............................................................................................................................................. 5 
DEFINITIONS  ................................................................................................................................................... 6 
1. BACKGROUND  .......................................................................................................................................... 12 
1.1.  Introduction ..............................................................................................................................................................................................  12 
1.2. Preliminary Progress – Vitamin C Intervention in  Experime ntal Septic Lung Injury  ........................................................  14 
1.3 Phase I Human Trial: Vitamin C Infusion In Human Sepsis: Preliminary Results From A Safety Trial  ......................... 17 
1.4. Potential Mechanisms of Action of Ascorbic Acid in Sepsis  ........................................................................................................ 19 
1.5. Ascorbic Acid Dose Selecti on ................................................................................................................................................................  19 
1.6. Study Rationale  ......................................................................................................................................................................................... 20 
2. OBJECTIVES  .............................................................................................................................................. 20 
2.1. Primary  Objecti ves ..................................................................................................................................................................................  20 
2.2. Hypothesis .................................................................................................................................................................................................. 21 
3. END -POINTS  ............................................................................................................................................. 21 
3.1.  Primary Endpoints  ..................................................................................................................................................................................  21 
3.2.  Secondary End Points  .............................................................................................................................................................................  21 
3.3. Focused Safety Analysis:  ........................................................................................................................................................................ 22 
3.3.1 Renal Monitoring Plan  .................................................................................................................................................................................................. 22 
3.3.2 Glucose Monitoring Plan  .............................................................................................................................................................................................. 22 
4. STUDY POPULATION  AND  ENR OLLMENT  .................................................................................................. 23 
4.1. Number/Source/Screening  ...................................................................................................................................................................  23 
4.2. Inclusion Crit eria ......................................................................................................................................................................................  23 
4.2.1 CITRIS -ALI Inclusion Criteria:  ................................................................................................................................................................................... 23 
4.3. Enrollment, Ra ndomi zation, and Study Initiation Time Window  ........................................................................................  25 
4.4. Informed Consent  ................................................................................................................................................................................. 25 
4.5. Randomization ...................................................................................................................................................................................... 25 
4.7. Minorities and Women  .......................................................................................................................................................................  25 
 
CITRIS Protocol Version  9 
 3 5. STUDY PROCEDURES  ................................................................................................................................. 25 
5.1.  Vitamin C or Placebo Administration  ...............................................................................................................................................  26 
5.2.  Drug Level Speci mens (venous blood)  .............................................................................................................................................. 26 
5.3.  Completion of Study Drug Administration  ......................................................................................................................................  26 
5.4. Premature Withdrawal from Treatment  ..........................................................................................................................................  27 
5.5.  Ventilator Procedures  ............................................................................................................................................................................  27 
5.6.  On-Study Fluid Management  ................................................................................................................................................................  27 
6. DATA COLLECTION  .................................................................................................................................... 28 
6.1. Backgro und Assessments ......................................................................................................................................................................  28 
6.2. Baseline/Hour 0 Assessments and Procedures  ..............................................................................................................................  29 
6.3. Assessments after Enrollment  ......................................................................................................................................................... 29 
7. STATISTICAL CONSIDERATIONS  ................................................................................................................. 30 
7.1. Statistical Metho ds ...................................................................................................................................................................................  30 
8. DATA COLLECTION AND  SITE MONITORING .............................................................................................. 31 
8.1. Data Collection  ..........................................................................................................................................................................................  31 
8.2. Site Monitoring  ......................................................................................................................................................................................... 31 
9. RISK  ASSESSMENT  ..................................................................................................................................... 32 
9.1. Risks of Active Study Drug  ..................................................................................................................................................................... 32 
9.2. Risks of Blood Dra ws ...............................................................................................................................................................................  32 
9.3. Minimi zation of Risks  .............................................................................................................................................................................. 32 
9.4. Potential Benefits  .....................................................................................................................................................................................  33 
9.5. Risks versus Benefits .............................................................................................................................................................................. 33 
10. HUMAN  SUBJECTS  ................................................................................................................................... 33 
10.1. Selection of Subjects  .............................................................................................................................................................................. 33 
10.1.1. Equitable Selection of Su bjects  .............................................................................................................................................................................. 33 
 
CITRIS Protocol Version  9 
 4 10.1.2.  Vulnerable Subjects  ................................................................................................................................................................................................... 33 
10.2. Informed Consent  .................................................................................................................................................................................  34 
10.3. Identification of Surrogates ............................................................................................................................................................... 34 
10.4. Justification of Surrogate Consent ...................................................................................................................................................  34 
10.5. Additional Safeguards for Vulnerable Subjects  ...........................................................................................................................  35 
10.6. Confidentiality  .......................................................................................................................................................................................  35 
11. ADVERSE EVENT REPORTING/SAFETY REPORTIN G .................................................................................. 35 
12. APPEND ICES ......................................................................................................................................... 38 
APPENDIX A:  Guidelines  for evidence  of infection  ................................................................................................................................ . 38 
APPENDIX B:   Pleiotropic Effects  of Vitamin C  ........................................................................................................................................ 40 
APPENDIX C:  Ventilator Procedures  ..........................................................................................................................................................  42 
C.1. Ventilator Management  .................................................................................................................................................................................................. 42 
C.2. Weaning  ................................................................................................................................................................................................................................ 43 
C.3. Definition of Unassisted Breathing ........................................................................................................................................................................... 44 
C.4. Definition of Ext ubation  ................................................................................................................................................................................................. 44 
C.5. Completion of Ventilator Procedures  ...................................................................................................................................................................... 44 
C.6. Removal from t he Ven tilator Management Protocol  ........................................................................................................................................ 45 
APPENDIX D:  FACTT LITE Conservative  Fluid  Management  Approach  ...........................................................................................  46 
APPENDIX E: Time Events Schedule  ...........................................................................................................................................................  47 
APPENDIX F:   Adverse  Events .......................................................................................................................................................................  48 
APPENDIX G: Modified SOFA Score Calculator  ........................................................................................................................................ 53 
APPENDIX H: P/F from S/F  Calculator  ......................................................................................................................................................  54 
REFERENCES CITED:  ....................................................................................................................................... 55 
 
 
CITRIS Protocol Version  9 
 5 ABBREVIATIONS  
 
ABG = Arterial blood gas  
AKI = Acute Kidney Injury 
ALI = Acute Lung Injury 
Ang-2 = Angiopoietin-2 
APACHE  = Acute physiologic and chronic 
health  evaluation  
AscA = Ascorbic Acid (Vitamin C)  
ARDS  = Acute Respiratory Distress  
Syndrome 
BIPAP  = Bi -level Po sitive Airway Pressure  
BMI  = Body Mass Index 
CCC = Clinical Coordinating Center 
CK = Creatinine Kinase  
CPAP  = Continuous Po sitive Airway  
Pressure  
CRP  = C- reacti ve protein  
Day 0 = Day of Randomi zations  
  DHA = Dehydroascorbic Acid  
DSMB = Data Safety Monitoring Board FACT T = Fluid and Catheter Treatment 
Trial  
FDA=Food and drug admi nistration  
FiO2  = Fraction of Inspired Oxygen 
FIP = Feces Induced Peritonitis  
GCS = Glasgow Co ma Scale  
ICU = Inte nsive ca re Unit 
IMV  = Int ermittent Me chanica l Ventila tion 
IRB = Institutional Review Board 
IVRS  = Interactive Voice Response System   
 
LPS = Lipopolysaccharide 
MBW  = measured body weight  
NFκB= Nuclear factor kappa B  
NHLBI  = National Heart Lung and Blood 
Institute  
NIV=Non -invasive ventilation 
NOS= Nitric oxide synthase 
OI = Oxygenation Index  = [mean airway 
pressure x F i02]/Pa02 
PaCO2= Partial pressure of arterial carbon 
dioxide 
PaO2 = Partial pressure of arterial oxygen 
PBW  = Predicted Body Weight 
PCT = Procalcitonin  
PCV = Pressure Contr ol Ventila tion 
PEEP = Positi ve End -Expira tory Pre ssure  
PIN = Personal Iden tification Numb er 
Pplat  = Plateau pressure  
PSV = Pressu re Support Ventilation  
PAOP  = Pul monary Artery Occlusion Pressure  
RAGE  = receptor for a dvanced glycation end 
products 
RCT = Rando mize
 d Controlled Trial 
SBT = Spontaneous Breathing Trial 
SIRS  = Syste mic Inflammatory Response 
Syndrome SOFA  =Sequential Organ F ailure Assessment 
SpO
2  = Oxygen Saturation 
TFPI = Tissue Factor Pathway Inhibitor  
TM = Thrombomodulin 
VFD = Ventil ator-free Day  
 
CITRIS Protocol Version  9 
 6  
DEFINITIONS  
 
Acute  Kidney Injury : Acute kidney injury network Stage 3 disease, defined as a t hreefold incre ase in 
creatinine from baseline or the n eed for dialysis 
Asian:  A person having origins in any of the original peop les of  the Far East, Southeast Asia, or the Indian 
subcontinent including, for example, Cambodia, China, India, Japan, Korea, Malaysia, Pakistan, the 
Philip pine Islands, Thailand, and Vietnam. 
Completing  48 hours of Unassisted Breathing (UAB) : Defined as the date (calendar day) that the 
subject reaches exactly 48 hours of UAB. Exam ple: if subject meets UAB at 1900 on 6/1/14 and does not 
return to assisted breathing ( AB), then the date of completing 48 hours of UAB would be 6/3/14. 
Date  of first UAB : Defined as the first day that the subject is on UAB from midnight to midnight. 
Example: if subject meets UAB at 1900 on 6/1/14, then the date of first UAB would be 6/2/14, as long as 
subject does not return to AB on 6/2/14. 
Extubation : Removal of an orot racheal, nasotracheal tube, or unassisted breathing with a trach eosto my 
Home : Level of residence or health  care facility where t he patient was residing prior to hospital 
admission  
NYHA: New York Heart Associati on Class IV subject s (defined as subjects who have cardiac disease 
resulting in inability to  carry  out physical ac tivity without disco mfort.  Symptom s of cardiac 
insufficiency or an anginal syndrom e may be present even  at rest.  If any physical acti vity is undertaken, 
discomfort is increased).  
Severe Sepsis : SIRS criteria plus suspected or known infection  plus organ dysfunction.  Since intubation and 
hypoxemi a is a requirement for enrollm ent into this  trial, participants will, by definition, m eet the SI RS 
criterion .   
Study  hospita l: Defined as the hospital where the  patient was rando mized and enrolled. 
Study  withdra wal: Defined as permanent withdrawal  from study before completion of study activ ities. 
This does not include those subjects who have completed the protocol procedures or stopped procedure s 
because they have reached unassisted breathing. If a patie nt or s urrogate requests withdrawal from the study  
the clinician should seek explic it per mission to continue data collection. 
UAB (Unassisted Brea thing) :  Spontaneously breathing with face mask, nasal prong oxygen, or room air, 
T-tube breathing, trach eosto my collar (m ask) breathing, or CPAP ≤ 5 without PSV or IMV assistance, or 
the use of noninvasi ve ventilation solely for sleep -disordered breathing.  Assisted breathing is any level of 
ventil atory  support at pressures higher that the unassisted breathing thresholds.  
  
 
CITRIS Protocol Version  9 
 7 Part I: Study Summary  
 
Title : Vitamin  C Infusion for  TReatment  In Sepsis Associated  Acute Lung I njury  
(CITRIS -ALI)  
Objec tive:  To assess the efficacy of a 96 -hour intravenous vitamin C infusion protocol (200 mg/kg per 24 
hours) in patients with established acute lung injury ( ALI) from sepsis. In this course of performing this phase 
II trial we will explore three hypotheses:  
 
Hypot hesis: 
Hypothesis 1A : Vitamin C  infusion will significantly attenuate sepsis associated  systemic organ failure as 
measured by Sequential Organ F ailure Assessment (SOFA) score  
Hypothesis 1B : Vitamin C infusion will attenuate sepsis associated  lung injury as assessed by oxygenation 
index and the VE 40 (see below)  
Hypothesis 1C : Vitamin C infusion will attenuate biomarkers of inflammation (C- Reactive Protein, 
Procalcitonin ), vascular injury ( Thrombomodulin, An giopoietin-2), alveolar epithelial injury ( Receptor For 
Advanced Glycation End Products), while inducing the onset of a fibrinolytic state ( Tissue Factor Pathway 
Inhibitor ).  
 
Study  Design:  
1.   Multi -center, prospective, rando mized, placebo- controlled clinical trial  
2.   A maximum of 170 patients will be enrolled  
3.  Participants will be randomized to receive either intravenous Vitamin C  (mixed in 5%  dextrose in 
water)  or placebo (5% dextrose in water)  
4.   Active treatment will contin ue for 96 hours , dischar ge from  study hospital, discharge from the 
ICU,  study withdrawal, or death, whichever com es first. 
5.   All participants will be followed for a total of 60 days.  
 
Analysis/ Interim Monitoring:  
1. The principal analysis will be on the basis of the intention- to-treat.  
2.  Protocol compliance will be monitored by the study team by presentation of 1st two enrolled 
subjects per site to the team.  This will take place via investigator conference call and will address challenges encountered.  Trial progre ss will be monitored by an independ ent Data and  
Safety Monitoring Board to determine if the study should stop for s afety  reasons.  As an early 
phase study it is important to collect as much data as possible.  For this reason the study will only be halted by the DSMB for reasons of patient safety concerns.  The first scheduled analysis will 
occur after the enrollment of 80 patients or semi -annually, whichever happens first.  The next 
review will occur af ter enrollment of the last enrolled subject , or semi -annually, whichever comes 
first.  In the event that safety concerns arise prior to the scheduled analysis, the DSMB may 
request an unscheduled review at any time. The Data and Safety Monitoring Board (DSMB) will 
also monitor trial quality.  
3. Regulatory compliance, GCP, and risk-based monitoring will be provided by an independent CRO. 
 
 
 
CITRIS Protocol Version  9 
 8 CITRIS -ALI Inclusion and Exclusion Criteria :  
The inclusion and exclusion criteria for the CITRIS -ALI trial is listed here and in the full CITRIS -ALI protocol. 
The definition of severe sepsis for this study is derived and defined as previously published in the referenced 
literature .i,ii,iii 
CITRIS -ALI Inclusion  Criteria:  
Patients must have suspected or proven infection, and meet 2 out of 4 of the criteria for Systemic Inflammatory 
Response (SIRS) due to infection, and be accompanied by at least 1 criterion for sepsis associated  organ 
dysfunction,  and meet all 5 criteria for Acute Respiratory Distress Syndrome (ARDS).  
1. Suspected or proven infection : (e.g., thorax, urinary tract, abdomen, skin, sinuses, central venous 
catheters, and central nervous system, see Appendix A).  
2. The presence of a systemic inflammatory response: Defined as: fever:  >38ºC (any route) or 
hypothermia:  <36ºC (core temp only), tachycardia:  heart rate > 90 beats/min or receiving medications 
that slow heart rate or paced rhythm, leukocytosis :  >12,000 WBC/µL or leukopenia:  <4,000 WBC/ µL 
or >10% band forms.  Respiratory rate > 20 breaths per minute or PaCO2 < 32 or invasive mechanical ventilation. 
3. The presence of sepsis associated  organ dysfunction:  (any of the following thought to be due to 
infection) 
a. Sepsis associated  hypotension (sys tolic blood pressure (SBP) < 90 mm Hg or an SBP decrease > 
40 mm Hg unexplained by other causes or use of vasopressors for blood pressure support (epinephrine, norepinephrine, dopamine =/> 5mcg, phenylephrine)  
b. Arterial hypoxemia (PaO
2/FiO 2 ≤ 300) or supplemental O2 > 6LPM. 
c. Lactate > upper limits of normal laboratory results  
d. Urine output < 0.5 ml/kg/hour for > two hours despite adequate fluid resuscitation  
e. Platelet count < 100,000 per mcL  
f. Coagulopathy (INR > 1.5)  
g. Bilirubin > 2 mg/dL  
h. Glasgow Coma Sc ale < 11 or a positive CAM ICU score  
4. ARDS characterized by all the following criteria  
a. Lung injury of acute onset, within 1 week of an apparent clinical insult and with progression of respiratory symptoms  
b. Bilateral opacities on chest imaging not explained b y other pulmonary pathology (e.g. pleural 
effusions, lung collapse, or nodules) 
c. Respiratory failure not explained by heart failure or volume overload 
d. Decreased arterial P aO2/FiO2 ratio ≤ 300 mm Hg 
e. Minimum PEEP of 5 cmH
2O  
  
 
CITRIS Protocol Version  9 
 9 CITRIS -ALI Exclusion Criteria:  
1. Known allergy to Vitamin C 
2. inability to obtain consent;  
3. age < 18 years;  
4. Not on a ventilator 
5. more than 48 hrs since meeting ARDS  criteria;  
6. No indwelling venous or arterial catheter in patients requiring insulin in a manner that requires glucose 
being checked more than twice daily (e.g. continuous infusion, sliding scale)  
7. Presence of diabetic ketoacidosis  
8. patient or surrogate or physician not committed to full support (not excluded if patient would receive all 
supportive care except for cardiac resuscitation);  
9. pregnancy or breast feeding, 
10. moribund patient not expected to survive 24 hours; 
11. home mechanical ventilation (via tracheotomy or noninvasive) except for CPAP/BIPAP used only for sleep -disordered breathing; 
12. on home O2  > 2LPM , except for with CPAP/BIPAP  
13. diffuse alveolar hemorrhage (vasculitis); 
14. interstitial lung disease requiring continuous home oxygen therapy; 
15. Active kidney stone 
16. Non English speaking; 
17. ward of the state (inmate, other).  
Primary Objective:  
To assess the efficacy of a 96 -hour high dose intravenous vitamin C infusion protocol (200 mg/kg per 24 
hours) in patients with established ALI/ARDS that results from severe sepsis. Patients will be randomized to 
receive either: 1) Placebo  (50 ml of 5% dext rose in water) or Vitamin C  (sterile L -ascorbic acid for injection at 
200 mg/kg per 24 hours with entire  calculated 24 hour dose diluted in 200 ml of 5% dextrose in water). One 
fourth of the 24 hour calculated dosage will be administered in 30 minute intr avenous infusions will occur every 
6 hours.  
 Endpoints:  
The CITRIS -ALI trial will depart from prior acute lung injury trials in that assessment of efficacy will not 
include 28- day all -cause mortality as a primary endpoint. As directed in RFA -HL-12-022, primary end points 
will focus on quantifiable measures of organ function and biomarker analysis (SOFA, CRP, Procalcitonin, 
Thrombomodulin) . For this phase II trial we propose co -primary endpoints. 
 
Primary Endpoint #1: Change in SOFA score at 96 hours as c ompared to baseline when compared to placebo.  
Primary Endpoint #2: C -Reactive Protein and Thrombomodulin at study hours  0, 48, 96, 168 when compared 
to placebo. 
 
Secondary Endpoints : 
• Oxygenation Index (FiO 2 x Mean Airway Pressure/ PO 2) at study hour 0, 48, 96, 168 if still intubated in 
ascorbate infused patient compared to placebo.  
• VE-40 (Vent RR x TV/Weight) x (PaCO 2/40) at  study hour 0, 48, 96, 168 if still intubated , in ascorbate 
infused patient compared to placebo 
• SOFA scores at hours 48, 96, 168 
 
CITRIS Protocol Version  9 
 10 • SOFA Score Components at hours 48,96, 168 
o PaO2/FiO2  
o SpO2/FiO2  
o Platelets  
o Total Bilirubin  
o Vasopressor status  
o GCS  
o Creatinine or Urine Output 
• Procalcitonin, Receptor for Advanced Glycation End Products, T issue Factor Pathway Inhibitor at 
study hour 0, 48, 96, 168  
• Ascorbate level at hour 0, 48, 96, 168 
• Ventilator Free Days to day 28 
• ICU- free days at day 28  
• All cause mortality to day 28  
• Hospital-free days at day 60 
 
Focused  Safety Analysis : Given that L- Ascorbate is an “acid” the drug manufacturer adjusts  the pH thus 
balancing pH at 7.4 and negating the acid effect of the drug.  Unexplained metabolic acidosis will be addressed 
per standard of care for each participating institution.  
 
Study  Drug  Dosing :  
 
1. First study drug do se (L-ascorbic acid or place bo) will be considered “Dose  1” and will be 
admi nistered within 6 hours of random ization  or the earliest available time post any clinically indicated 
procedure which requires the patient to be off the unit. All doses will be administered in the ICU.  Patients receiving vitamin C will receive 25% of the total daily calculated dosing (200mg/kg/24 hours) and will be infused over 30 minutes for this first dosing . 
2. Subsequent doses  which represent 25% of the day’s total dose will be infused every six hours through 
96 hours (+/ - 3 hours).  
a. Timing of Dose 2 will be triggered by the physician order for q 6 hour administration and will therefore be listed on the bedside MAR.  As such, timing of Dose 2 may be out of the +/ - 3 
hour window and will not trigger a protocol deviation. 
b. If for any reason any other m aintenance dose is not ad ministered within window, the dose will 
be skipped and the next scheduled dose will be given and documented in the data collection tool.  
 
Drug level specimens (venous blood) : Septic patients exhibit subnormal plasma ascorbate levels. Phase I 
studies performed at Virginia Commonwealth University  (VCU) show mean ascorbate levels of 17.5 µM 
(normal human ascorbate levels 60 to 70 µM). Entry ascorbate levels will be drawn.  
 
The target plasma range for modifying pro-inflammatory biomarkers and for attenuating vascular injury 
was obtained from the phase I safety trial and is greater than 500 µm  as measured  24 hours after initiation 
of Vitamin C infusion. The day 2 – 7 plasma ascorbate levels are expected to be betw een 500 to 1000 µM 
based on phar macokinetic studies generated during the phase I trial ( VCU trial was entitled: Vitamin C 
Infusion in Human Sepsis).  
 
Blood drawn for ascorbate levels and biomarkers will occur at hour 0 (prior to the first infusion), hour 48 (+ 
 
CITRIS Protocol Version  9 
 11 or – 3 hours as long as it is drawn prior to Infusion 9), hour 96 (+ or – 3 hours as long as it is drawn at least 
3 hours post Infusion 16), and hour 168 (+ or – 6 hours).  If patient is moved out of the ICU to another hospital unit, DO continue to collect blood for biomarkers and ascorbate levels.   
 
If arterial line is removed prior to hour 168, do not collect arterial blood for PO2 analysis (SOF A Score 
component).   
 
Completion  of study drug administration: Study drug administration will be stopped when one of the 
following conditions is met, whichever co mes first:  
1. Final drug dose at 96 hours 
2. Discharge from  study hospital 
3. Loss of indwelling venous or arterial catheter  with no intent to replace the line , making it impossible to 
monitor glucose levels via central laboratory without multiple peripheral sticks.   
4. Discharge from the ICU  
5. Withdrawal from study  
6. Death  
 
 
           
 
 
CITRIS Protocol Version  9 
 12  
 
Part II:  Study  Description Vitamin C Infusion for 
TReatment In Sepsis Associated  Acute Lung Injury  
CITRIS -ALI 
1. Background  
 
1.1. Introduction  
 
Pneu monia and extrapulmonary seps is accou nt for 50-65% of all ALI c ases and m ortality is high.  Rising 
rates of hospitalization and death due to sepsis continue to be a worsening global health care problem.iv A large 
fraction of patients with severe sepsis develop acute lung injury (ALI) or its severe form, the acute respiratory 
distress syndrome (ARDS).v The pathogenesis of ALI is characterized by activation of tissue inflammation, 
oxidant mediated tissue injury and increased vascular leak. At a molecular level, sepsis is associated with 
activation of pro -inflammatory mediators driven by transcription factor nuclear factor kappa B ( NFκB). The 
pathogenesis of ALI is characterized by activation of tissue inflammation, oxidant mediated tissue injury and 
increased vascular leak. These mediators are important for host defense against invading bacteria, but their 
uncontrolled and excessive production ultimately contributes to the pathogenesis of ALI.  
The lung is an important target of inflammatory mediators in severe sepsis
vi and increased pulmonary NF κB 
drives inflammatory mediators in severe sepsis .vii Reactive oxygen species (ROS) produced by lung cells 
oxidize vital lung proteins and activate redox-sensitive pathological signaling pathways. An extensive body of 
evidence shows a crosstalk between the cellular signaling pathways and the cellular redox state through multiple mechanisms. However, exuberant ROS synthesis may also damage cells and host tissues, and , thus, 
contribute to the pathogenesis of ALI. Although the potential role of antioxidant enzymes and scavengers of ROS in reducing the severity of ALI has been recognized, no single agent or treatment strategy has shown sufficient promise for use in routine clinical practice.  
 Ascorbic acid is an essential vitamin for humans, primates, guinea pigs, and a few other animals and insects that 
lack the enzyme L -gulono-γ-lactone oxidase. A scorbic acid is an essential vitamin for humans, primates, guinea 
pigs, and a few others.
viii Ascorbic acid is transported into specialized cells as reduced ascorbic acid (AscA ) by 
sodium dependent ascorbic acid transporter s (SVCT -1 and SVCT-2) or in most cells in its oxidized form as 
dehydroascorbic acid (DHA) via facilitative glucose transporters.ix,x When DHA is transported via the glucose 
transporters, it is rapidly reduced and trapped inside the cell, where it accumulate s as reduced ascorbic acid. 
Although ascorbic acid circulates in normal human plasma at approximately 60 - 70 µM, it accumulates in 
millimolar concentrations in host defense cells.xi Together with glutathione, AscA  constitutes a primary line of 
defense against ROS and participates in the recycling of other antioxidants such as vitamin E. A growing body 
of evidence supports the notion that vitamin C is “negatively” involved in the pathogenesis of sepsis.xii 
 
CITRIS Protocol Version  9 
 13 Subnormal a scorbate concentrations are common features of patients with sepsis. Furthermore, plasma 
ascorbate levels correlate inversely with multiple organ failurexiii and directly with survival.xiv Despite all the 
evidence, ascorbate is not used in a clinical setting.  
 
At physiological pH, AscA  dissociates to form dehydroascorbic ascorbate.
xviii
xxiii
xxvii
xxviii
xxxii
xxxiii xxxivxv Ascorbate functions as an 
antioxidant by inhibiting cell death induced by hydrogen peroxidexvi and DNA damage induced by oxidative 
stress.xvii Ascorbate also functions as a cofactor for v arious enzymatic hydroxylation reactions and is involved 
in the biosynthesis of collagen, carnitine and norepinephrine.,xix,xx As noted, circulating levels of ascorbate 
are low in patients with sepsis and plasma ascorbate correlates directly with survival and inversely with multiple organ failure. Similar results have been observed in animal models of sepsis. Ascorbate administration improves capillary blood flow, liver function and arteriolar responsiveness in experimental models of sepsis.
xxi,xxii, In 
mice injected with pathogenic bacteria, prior ascorbate depletion results in decreased survival.xxiv Recently 
ascorbate was shown to reg ulate the stability of a master transcription factor HIF -1α.xxv As noted, circulating 
levels of ascorbate are low in patients with sepsis and plasma ascor bate may protect microvascular function by 
two distinct mechanisms: a) by inhibiting NADPH oxidase activ ation and b) by increasing endothelial nitric 
oxide synthase (eNOS) activity, and subsequently suppressing expression of NADPH oxidase, inducible nitric oxide synthase and tissue factor.
xxvi However, little is known about the effects of ascorbate administrati on in the 
setting of sepsis- mediated ALI. Gram -negative sepsis is a leading cause of ALI/ARDS and multiple organ 
failure.  Intra -peritoneal injection of a single bolus of bacterial LPS precipitates a systemic inflammatory 
response that resembles in many ways the observed clinical profile of sepsis including ALI and ARDS.  It is 
well known that LPS activates inflammatory cells such as polymorphonuclear leukocytes, monocytes, macrophages and lymphocytes. Besides immune cells, microvascular endothelial cells i n multiple organs also 
become activated in sepsis and may contribute to amplification of the inflammatory response. Moreover, it is generally agreed that it is not the bacterial infection itself, but rather the inflammatory response to infection that is the predominant determinant of outcome in sepsis.
xxix, xxx In support of this hypothesis, it has been shown that 
septic stimuli initiate activation of transcription factors that transactivate multiple genes such as pro -
inflammatory cytokines, adhesion molecules and chemokines by endothelial cells.xxxi, Not s urprisingly, 
efforts to block single components of the sepsis- associated inflammatory pathways have had little impact on 
patient survival and little progress has been made in improving outcomes., 
 Summary:  Sepsis is a common clinical problem that frequently leads to widespread acute vascular injury that 
is clinically manifested by multiple organ failure. One of the most frequent organs injured following onset of sepsis is the lung.
xxxvi
xxxvii
xxxviiixxxv At present, no truly spe cific therapy is available for acute lung injury (or other organ 
injury) that occurs in association with sepsis. The preliminary data presented below suggests that ascorbic acid may present a means by which sepsis -associated vascular injury can be interrup ted or reversed. AscA  has been 
intravenously infused in humans in high dosages previously. Nathens et al infused 1.5 grams of AscA  every 8 
hours into surgical trauma ICU patients daily for 28 days with no adverse events.  Muhlhofer et al infused 
high dose ascorbic acid (7500 mg) intravenously into human volunteers daily for 7 days and showed no adverse events.  Finally, Tanaka et al infused high-dose ascorbic acid (66 mg/kg/hour, average 110 grams 
for 70 kg human) for 24 hours into patients with over 50% to tal body surface area burns.  No 
abnormalities in hematologic, hepatic, or renal function was associated with ascorbate infusion at day 7 following ascorbate administration. The scope of the study being presented in this phase II proof of concept trial involves the use of intravenously administered AscA  as a future potential therapy for sepsis associated  
acute lung injury. Previous basic scientific  research currently suggests that AscA  can attenuate sepsis-
associated vascular injury. Further, prior data obt ained from our phase I human safety studies suggests that 
high doses of AscA  can be administered intravenously with little or no adverse events. Given these realities  
and the results of our phase I trials in human sepsis, we propose that intravenous AscA  may present a unique 
therapy to improve the outcomes in human sepsis associated  acute lung injury. 
 
CITRIS Protocol Version  9 
 14  
 
 
1.2. Preliminary Progress  – Vitamin C Intervention in  Experimen tal Septic Lung Injury  
 
We sought to examine the biological effects of ascorbic acid (AscA ) infusion on systemic inflammatory 
responses and acute organ injury associated with bacterial sepsis. To accomplish  this, we created a durable 
model of septic shock and acute lung injury in wild type C57BL6 mice. Beyond the creation of an animal model 
system of acute lung injury, a primary goal of these studies was to determine the extent to which ascorbic acid could be empl oyed as an interventional therapy  for bacterial sepsis. Multiple prior animal studies published 
over the years have examined pharmacological agents (e.g., methyl prednisolone, ibuprofen, simvastatin ) and 
biological agents (e.g., monoclonal antibody to tumor necrosis factor alpha, interleukin -1 receptor antagonist) as 
potential sepsis therapies. Many agents have shown efficacy in sepsis when the agent was administered prior to 
induction of sepsis . In a “real world” setting, however, any intervention for seps is will follow the development 
of symptoms and altered physiology. 
 In preliminary studies described here, an interventional approach (agent administered after onset of sepsis) was 
employed to test the impact of ascorbic acid infusion on the course of sepsis associated  acute lung injury. Sepsis was induced in mice by 
intraperitoneal (IP) administration of E coli lipopolysaccharide (LPS, 0111:B4) at a concentration of 10 mcg/gram of body weight. Animals had average body weights of 30 grams.   Our first goal was to examine whether AscA  infusion altered the course of 
murine sepsis. In these studies, mice received IP LPS at the stated dose. Thirty  minutes following LPS infusion, 
animals received intraperitoneal either the reduced form of vitamin C ( AscA ) 
or the oxidized form of vitamin C dehydroascorbate (DHA)  at doses of 
200 mg/kg of body weight . Both the reduced form and the oxidized form 
were employed in separate experiments. Following LPS infusion, 
animals were then given  free access to food and water. Mortality was observed 
over the ensuing 60 hours. Figure 1  shows Kaplan -Meier survival curves of 
septic mice treated with AscA  and DHA. These studies show that 
mortality induced by E coli sepsis in wild type mice was significantly improved by both ascorbic acid forms during the 60 hour observation period.  
Figure 1
Figure 2
 
CITRIS Protocol Version  9 
 15 Sepsis is frequently accompanied by acute lung injury (ALI). Sepsis associated  ALI is characterized by acute 
pulmonary edema and respiratory failure. Pulmonary edema results from loss of pulmonary mi crovascular 
endothelial integrity that leads to loss of endothelial “barrier function.” There is subsequent flooding of the dry 
airspaces of lung with plasma and cellular constituents. ALI is also 
characterized by intense sequestration of activated polymorphonuclear neutrophils (PMN). We assessed the loss of pulmonary microvascular barrier function using bronchoalveolar lavage fluid  (BAL F) protein 
analysis 16 hours following LPS infusion. Figure 2  shows that LPS treated 
mice exhibit significant increases in  BAL F protein, indicating a loss of 
barrier function. AscA  treatment  significantly attenuated microvascular 
injury as assessed by BAL F protein. 
   In a second model of sepsis (fecal induced peritonitis, FIP) , lungs were 
removed and total RNA isolated. Quantitative real time PCR (QPCR) was performed for myeloperoxidase mRNA (surrogate for assessing the extent of PMN sequestration). Figure 3  shows that untreated septic murine 
lung is characterized by significan t PMN sequestration. Both AscA  and dehydroascorbic acid (DHA) 
significantly attenuated PMN sequestration.  
 Figure 4  shows H&E stains of 
sections of lungs removed at 16 hours following onset of feces induced 
peritonitis . As seen in this figure, 
intense c ellular sequestration and 
septal edema is present in the lung of unprotected FIP-treated mice. In 
contradistinction, AscA  treatment 
significantly attenuated the histological findings of murine sepsis.  
 Sepsis is characterized by the development of 
a severe proinflammatory state with the rapid 
onset of expression of multiple NF κB driven 
genes. Figure 5 shows that septic murine 
lung is characterized by the pre sence of 
significant expression of two nuclear NF κB 
activated genes examined via quantitative 
real time PCR (KC [murine IL -8 homologue], 
LIX).  AscA  and DHA administered 
following onset of sepsis significantly 
reduced the expression of these genes.  
 
The image part with relationship ID rId23 was not found in the file.
The image part with relationship ID rId23 was not found in the file.
Figure 5
Figure 3
FIP
 FIP-AAFigure 4
 
CITRIS Protocol Version  9 
 16 Bacterial sepsis is virtually always accompanied by disordered 
coagulation and is frequently   associated with disseminated intravascular coagulation (DIC). A large body of significant scientific literature has documented the disruption of microvascular 
function/integrity induced by DIC.
xxxix Uncontrolled DIC uniformly 
induces act ivation of multiple proinflammatory coagulation-
associated proteases that activate both intrinsic and extrinsic coagulation pathways. The resulting “cascade effect” produces 
widespread microvascular thrombus formation and subsequent multiple organ injury and failure. DIC 
frequently produces acute lung injury.
xl We examined the extent of microvascular 
thrombosis in the lungs of our LPS- treated  wild type mice. Sixteen 
hours after LPS infusion lungs were fixed, paraffin embedded, and H&E  stained sections examined for the presence of microthrombi. 
Figure 6, shows that untreated septic lungs exhibit extensive 
microvascular thrombosis (arrows). However, in AscA -treated 
septic lungs ( Figure 6), virtually no microthrombi were observed . A 
Zeiss light microscope outfitted with a Axiovision counting software program was used to label and quantify 
microthrombi between multiple lung sections. Figure 7 shows that LPS (without treatment) produced highly 
significant numbers of micro thromboses. AscA  intervention in septic mice abolished virtually all 
microthrombi. Similar findings were obtained in DHA treated lungs (data not shown).  
Following the onset of sepsis, multiple studies now show that sepsis- associated activation of 
Tissue Factor (factor III) is the sentinel event 
that induces the coagulation factor cascade leading to DIC. In further  preliminary studies, 
we examined the expression of tissue factor in the lungs of septic mice using  QPCR. Figure 8 
shows that both AscA  and DHA dramatically 
attenuated the expression of tissue factor in septic lungs while inducing the inhibitor profibrinolytic peptide tissue factor pathway inhibitor (TFPI). 
 
Summary Of Preliminary Animal Studies : During the animal modeling studies, no unt oward effects of AscA  or 
DHA on animal subjects was observed . The preliminary data shows convincingly that ascorbic acid is capable 
of significantly altering the course of biological events which arise following the onset of bacterial sepsis that 
lead to lung injury. Our results show significant impacts on sepsis induced mortality with both the r educed and 
oxidized forms of AscA . 
 
The image part with relationship ID rId23 was not found in the file.
LPS+AA LPSFigure 6
Figure 8
Control LPS LPS/AA LPS/DHAFigure 7
 
CITRIS Protocol Version  9 
 17 1.3 Phase I Human Trial: Vitamin C Infusion In Human Sepsis: Preliminary Results From A Safety 
Trial  
Our animal m odeling studies strongly suggested that vitamin C augmentation reverses detrimental septic 
biology that leads to lung injury. On the strength of these studies, we proceeded with a human trial. In 2010, 
following IRB approval, a phase I, randomized, double blind, placebo- controlled trial testing the safety of 
parenteral vitamin C in patients with severe sepsis was initiated at the VCU Medical Center. All patients enrolled, regardless of study arm, received full ICU standard of care. Patients were randomized to placebo (5% 
dextrose/water, D5W), low dose vitamin C (50 mg/kg/24hr), or high dose vitamin C (200 mg/kg/24hr). The calculated 24 hour vitamin C dose was divided into four equal doses and administered intravenously (in 50 ml 
D5W) over 30 minutes every 6 hours for 96 hours. Vital signs were monitored every 5 minutes during infusion 
and for 45 minutes afterwards by bedside ICU Nursing and the investigative team. Hypotension , tachycardia , 
and nausea/vomiting  and hypernatremia were the primary safety outcomes assessed. A multi -departmental 
data safety monitoring board oversaw patient enrollment into the trial. Serum/plasma specimens were obtained 
every twelve hours for 2 days, then once daily for two days. Enrollment:  Over a 1 year period, twenty-four 
patients  were randomized to the three groups ( Placebo, 4M, 4F, age 54-68 yrs.), ( Lo-VitC, 5M, 3F, age 30- 70 
yrs.), ( Hi-VitC, 4M, 4F, age 44-92 yrs.). APACHE II score at Enrollment : Mean APACHE II scores between 
groups were: Placebo - 20.4 (range: 15-29), Lo -VitC: 20.2 (range: 12-33), and Hi -VitC: 24 (range: 17-33) 
respectively. The groups were statistically identical.  
Phase I Primary Outcomes: Safety of Vitamin C Infusion : Safety of vitamin C infusion was the primary focus 
of this trial. During the 96 hour infusion period, no patients were withdrawn due to identified negative outcomes (hypotension, tachycardia, nausea/vomiting, or hypernatremia ). Infusions were halted in one patient (Hi -VitC) 
following infusion #14 (80hrs ) for a ventricular arrhythmia later determined by Cardiology to be artifact. This 
patient is included in the analysis. One patient (Hi- VitC) was transferred to another facility at 48 hours at the 
insistence of family and was lost to follow up. 
Plasma Ascorbate Levels in Human Sepsis: The impact of 
Vitamin C Infusion: Vitamin C levels were quantified by 
HPLC in all patients at enrollment then at defined intervals to 96 
hours. Ascorbate levels in all septic p atients at enrollment were 
subnormal (hyposcorbic) at 17.9 ± 2.4 µM (normal 50 – 70 µM) and were not significantly different at baseline. Figure 9 shows 
the change in plasma ascorbate levels through time across patient groups. Ascorbate levels rose rapidly  in the two 
treatment groups and were significantly higher than placebo within twelve hours (Lo -VitC vs. placebo P<0.005, Hi- VitC vs. 
placebo p<0.0005) remaining consistently elevated for 96 hours. 
Ascorbate levels in the Hi -VitC group were significantly h igher than the Lo-VitC group from the 12 hour point 
forward. These data show that an intermittent ascorbate infusion protocol (every 6 hour) produces sustained steady state levels.  
Figure 9
 
CITRIS Protocol Version  9 
 18 Sequential Organ Failure Assessment (SOFA) Scores  SOFA 
scores obtained ar e robust indicators of mortality during critical 
illness.xli Increases in SOFA scores during the first 48 hours of ICU 
care predicts a mortality rate of at least 50%. Initial SOFA scores at 
enrollment were: placebo – 13.3 ± 2.9, Lo- VitC – 10.1 ± 2.0, and Hi-
VitC 10.8 ± 4.4 and were not significantly different  across groups. Figure 10 shows that patients treated with high dose of vitamin C 
exhibited significantly lower SOFA scores when compared to placebo over the 96 hour period. SOFA scores among treated patients 
did not exhibit any subsequent rise whereas patients in the placebo 
group exhibited a gradual rise in scores. Though the cohort size is 
limited, these early data suggest that vitamin C infusion attenuates 
systemic organ injury associated with sepsis.  
Phase I Trial Secondary Outcomes:  Following enrollment 1) Days on vasopresso r (DOVP), 2) ventilator free 
days (VFD), and 3) ICU days (ICUD), were monitored as 
secondary outcomes.  We observed trends for fewer DOVP and 
ICUD and more VFD in the Lo -VitC patients, but the numbers 
were small and statistically insignificant. Though this  study was 
not powered to assess mortality, we present the results of 28 day 
all-cause mortality as a prospectively identified secondary 
outcome ( Fig 11). In the placebo group we found a 63% mortality 
(5 of 8 patients died). In the Lo-VitC, 3 of 8 patients died for 38% 
mortality, and 4 of 7 patients died in the Hi- VitC for a mortality 
of 57%. The  data showed in figure 11 further attests to the safety o f the vitamin C dosing regimens in that there 
was no additional added mortality among the treatment group patients when compared to placebo.  
Vitamin C Infusion Attenuates Biomarkers of Inflammation and Endothelial Injury In Patients with Severe 
Sepsis Sera obtained from enrolled subjects was analyzed for three biomarkers: C -reactive protein   (CRP), 
procalcitonin (PCT), and thrombomodulin 
(TM). CRP and PCT were quantified as surrogates for inflammation while TM was employed as a surrogate for endotheli al injury. 
At enrollment, biomarker levels across the three groups were not significantly different. CRP and PCT levels in all patient groups started high and trended down over time ( Fig 1 2). Of 
importance, patients randomized to receive low or high dose vitamin C exhibited more rapid 
reductions in PCT and CRP levels than patients randomized to placebo, achieving significantly lower levels when compared to their own baseline by 48 hours (p<0.05). Thrombomodulin levels in patients randomized to placebo, tho ugh not different at baseline, 
began increasing, becoming significantly elevated beyond 36 hours remaining significantly elevated when compared to vitamin C treated patients ( Fig 1 3). Vitamin C treated patients did not exhibit the 
increases in TM levels ob served in placebo -infused patients. Our 
The image part with relationship ID rId23 was not found in the file.
The image part with relationship ID rId23 was not found in the file.
Figure 12
Figure 10
Figure 11
Figure 13

 
CITRIS Protocol Version  9 
 19 preliminary results suggest for the first time that vitamin C infusion produces early reductions in 
proinflammatory mediators in patients with severe sepsis. The results further suggest that vitamin C infusion  
  Summ ary of Preliminary Phase I Safety Studies in Human Sepsis:  During phase I human study/trial no 
untoward/adverse effects of intravenous vitamin C infusion were observed in any patient during the 96 hour 
treatment protocol. The preliminary data gathered suggests that vitamin C is capable of significantly altering the 
course of organ failure, which  arise s in humans following the onset of bacterial sepsis . Biomarker data also 
suggest that vitamin C infusion attenuates proinflammatory peptide expression, a process that contributes to sepsis mediated acute lung injury. Further, ascorbic acid  infusion prevented subsequent increases in plasma 
thrombomodulin (an indicator of vascular injury). 
 
1.4. Potential Mechanisms of Action of Ascorbic Acid in Sepsis  
 
• Our experimental data in two murine models of sepsis induced lung injury suggest that vitamin C when 
infused acts in a pleotropic manner, attenuating NF κB inducible genes (chemokines, tissue factor) while 
boosting expression of genes leading to active fibrinolysis (i.e., tissue factor pathway inhibitor). 
• Humans lack L -gulono-γ-lactone oxidase, the final enzyme in vitamin C biosynthesis.xlii 
• Sodium- dependent vitamin C transporters move vitamin C into cells in reduced form or via facilitative 
glucose transporters in  oxidized form as dehydroascorbic acid (DHA).xliii DHA is rapidly reduced and trapped 
intracellular as reduced vitamin C or L -ascorbic acid.  
• Though vitamin C circulates in normal human plasma at 60-70µM, it accumulates normally in millimolar 
concentrations in host defense cells (i.e., neutrophils, platelets, macrophages) and endothelium .xliv 
Together with glutathione, vitamin C constitutes a primary line of defense against ROS and promotes 
recycling of other antioxidants (e.g., vitamin E). 
• Subnormal plasma vitamin C concentrations in septic patients correlate inversely with multiple organ failure 
and directly with survival. Vitamin C depletion in sepsis results from: 1) ascorbate consumption by reduction of plasma free iron, 2) ascorbate consumption by the scavenging of aqueous free radicals, and 3) by destruction of DHA.
xlv Sepsis associated  vitamin C destruction permits uncontrolled oxidant activity.  
• Clinical protocols currently in use for hospitalized septic patients are inadequate to normalize plasma vitamin 
C levels.xlvi 
• Ascorbate infusion into septic animals: 1) improves survival, corrects hypotension,xlvii
xlviii improves capillary 
blood flow,  protects endothelial barrier function,xlix attenuates peroxynitrite formation,l attenuates ALI, 
and disrupts lung capillary microvascular thrombosis (see preliminary murine data above).  
 
1.5. Ascorbic Acid Dose Selection  
 
Dosing and bio-distribution data in humans show that pharmacological concentrations of vitamin C can only be 
attained following intravenous administration.li Dosage selection for this trial was determined both from animal 
modeling, examining the biological effectiveness in a lung injury model system and from the recently conducted randomized double blind phase I human sepsis safety trial. The 200 mg/kg/24 hour IV dosing protocol was determined from quantification of plasma ascorbate levels and from assessing the impact on SOFA scores. Further, the dosage was selected following observation of the 200 mg/kg/24 hour regimen on biomarker levels.  
 
 
CITRIS Protocol Version  9 
 20 1.6. Study Rationale 
 
The purpose of this study is to assess the efficacy of intravenously infused ascorbic acid therapy for pat ients 
with sepsis associated  ALI.  By restricting the population to those we believe to have both infection and 
evidence for organ dysfunction ( severe sepsis), this study targets a disease  process and population that has 
been best studied in anim al model s and by a small  RCT. By focusing on sepsis associated  ALI , we have 
selected a group that has a higher disease burden than sepsis alone and thus likely to have both increased 
mortality  and an  increased opportunity for benefit, including a reduction in the requirement for m echanical 
ventilation. Given that the mortality and ventilator days are signif icant in patients with sepsis associated  ALI, 
we believe t here is real opportunity for i mproved clinical outco mes if the right interventional agent can be  
identified. In choosing the SOFA scores , and biomarkers of inflammation , vascular injury, and coagulation, as 
the primary outcom es, we will b e able to d etect changes in cli nical o utcomes that are i mportant for proving 
proof of concept. 
 
2. Objectives  
2.1. Primary  Objectiv es 
To assess the efficacy of a 96 -hour high dose intravenous vitamin C infusion protocol (200 mg/kg per 24 
hours) in patients with established ALI/ARDS that results from severe sepsis. Patients will be randomized to 
receive either: 1) Placebo  (50 ml of 5% dext rose in water) or Vitamin C  (sterile L -ascorbic acid for injection at 
200 mg/kg per 24 hours with entire  calculated 24 hour dose diluted in 200 ml of 5% dextrose in water). One fourth of the 24 hour calculated dosage will be administered in 30 minute intr avenous infusions will occur every 
6 hours.  
 
Clinical, physiological, and biomarker data will be collected at various time points while on study (See Appendix G). All data collected below will occur at the following timepoints: hour 0 (collected 
within the 24 hours prior to randomization, or post randomization, but pre-infusion), hour 48 (a timepoint prior to infusion 9), 96 (a timepoint close to hour 96 and after infusion 16), hour 168 (a 
timepoint close to hour 168)  
  : 
• VS (Body weight, blood pressure, heart rate, Temperature, mean arterial pressure, oxygen 
saturation, central venous pressure, glasgow coma score)  
• Vasopressor use (amount and type) (mcg/kg/min)  
• Ventilator data – Is the patient on or off vent? 
 If on mechanical  ventilation : Mean Airway Pressure, tidal volume, Peak Inspiratory 
Pressure, FiO2, Respiratory Rate, Plateau Pressure, Positive End Expiratory Pressure (data recorded from chart at the 8am time point or closest time point to 8am available)  
• Arterial Blood G ases: pH, PaO 2, PaCO 2, SpO 2  - for as long as subject has arterial line 
• Laboratory (Sodium, Potassium , Chloride, Metabolic Glucose,  Hemoglobin, Hematocrit , 
Platelets, White Blood Cell Count, Creatinine, Blood Urea Nitrogen, Bilirubin (data recorded from ch art at the 8am time point or closest time point to 8am available).  
• Biomarker blood sample 
• Sequential Organ F ailure Assessment Score (SOFA): (if intubated use PaO2/FiO2 ratio for 
calculation.  If not intubated see Appendix H for caluculating FiO2 and PaO2/FiO2  from SpO2 . 
Calculate using the worst value in the 24 hours preceding the Score time point for each component. See Appendix G for Modified SOFA Score Calculator.  
 
 
CITRIS Protocol Version  9 
 21  
2.2. Hypothesis  
Hypothesis 1 A: Vitamin C  infusion will significantly attenuate sepsis associated  systemic organ failure as 
measured by Sequential Organ Failure Assessment (SOFA) score,  
Hypothesis 1 B: Vitamin C infusion will attenuate sepsis associated  lung injury as assessed by the oxygenation 
index and the VE40 
Hypothesis 1C : Vitamin C infusion will attenuate biomarkers of inflammation (C- Reactive Protein , 
Procalcitonin ), vascular injury ( Thrombomodulin, Angiopoietin-2), alveolar epithelial injury (Receptor for 
Advanced Glycation End  Products), while inducing the onset of a fi brinolytic state (Tissue Factor Pathway 
Inhibitor ).  
 
3. End-Points 
 
Analysis of the primary, secondary and other endpoints will be conducted on an intention- to- treat (as 
random ized) b asis. 
 
3.1. Primary E ndpoint s 
 
Primary Endpoint #1: Change in SOFA score at 96 hours as compared to baseline when compared to placebo.  
Primary Endpoint #2: C -Reactive Protein and Thrombomodulin at study hours  0, 48, 96, 168 when compared 
to placebo. 
 
Explanation For The Choice of Primary Endpoints : The phase I trial was a safety trial and numbers of patients 
studied were small. The SOFA score was chosen as the "physiological primary endpoint" due to the prompt 
and significant reductions in the SOFA score observed in the high dose vitamin C group. T he SOFA score, 
though not a primary lung function score, contains the PaO 2/FiO 2 ratio in its calculation. We have chosen C-
Reactive Protein  and Thrombomodulin as broad indicators of inflammation and vascular injury to serve as the 
primary endpoint biomarkers.  
 
3.2. Secondary End Points  
 
Secondary Endpoints : 
• Oxygenation Index (FiO 2 x Mean Airway Pressure/P aO2) at study hour 0, 48, 96, 168 if still intubated 
in ascorbate infused patient compared to placebo.  
• VE-40 (Vent RR x TV/Weight) x (PaCO 2/40) at  study hour 0, 48, 96, 168 if still intubated, in ascorbate 
infused patient compared to placebo 
• SOFA scores at hours 48, 96, 168 
• SOFA Score Components at hours 48,96, 168 
o PaO2/FiO2  
o SpO2/FiO2  
o Platelets  
o Total Bilirubin  
o Vasopressor status  
o GCS  
 
CITRIS Protocol Version  9 
 22 o Creatinine or Urine Output 
• Angiopoietin-2, Procalcitonin, Receptor for Advanced Glycation End Products, T issue Factor Pathway 
Inhibitor at study hour 0, 48, 96, 168  
• Ascorbate level at hour 0, 48, 96, 168 
• Ventilator Free Days to day 28 
• ICU- free days at day 28  
• All cause mortality to day 28 
• Hospital-free days at day 60 
 
VE40 is a bedside pulmonary dead- space calculation and is defined as the minute ventilation needed to 
bring PaCO 2 to 40 mm Hg.lii Ventil ator Free Days or VFDs to day 28 are defin ed as the n umber of days 
from the ti me of initiating unassisted breathing to day 28 after random ization, assu ming surv ival for at least 
two consecutive calendar days after initiating unassisted breath ing and continued unassisted breathing to 
day 28.  If a patient returns to assisted br eathing and subsequently achieves unassi sted breathing to day 28, 
VFDs will be co unted from  the end of the last period of assisted  breathing to day 28.  A period of assisted 
breat hing lasting less than 24 hours and for the purpose of a surgical procedure w ill not co unt agains t the 
VFD calculation. If a patie nt was receiving assi sted br eathing at day 27 or dies pr ior to day  28, VFDs will 
be zero.  Patients transfe rred to another hos pital or other health care facility will  be followed to day 28 to 
assess this endpoint. ICU - and Hospital-free days to day 28 and day 60 are defined as the number of days 
alive between day 1 and day 28 and day 1 and day 60 which were spent outside the ICU or outside of the 
hospital respectively.  
 
3.3. Focused Safety Analysis : 
 
The current trial will be enrolling patients with sepsis associated  acute lung injury. We therefore expect that 
many of these patients will have some degree of organ dysfunction.  
3.3.1 Renal Monitoring Plan  
Patients with sepsis are at high risk of metabolic acidosis (including lactic acidosis). To prevent the possibility 
of metabolic acidosis due to drug administration, the study drug is formulated  to a neutral pH of 7.4. Therefore, 
we do not anticipate the need for additional monitoring of acid/base balance beyond standard-of- care provided 
at each inst itution. Any observed abnormalities will be evaluated according to standard -of-care practice and 
documented in the research record. 
3.3.2 Glucose Monitoring Pla n 
Guidance for blood glucose monitoring in patients enrolled in the CITRIS- ALI Trial: 
Ascorbic acid is known to artefactually raise  POC blood glucose readings by all POC devices except  the 
StatStrip glucometer. H owever, it does not raise blood glucose readings from a basic metabolic panel or glucose 
results using the gas lab.  Thus, extreme care must be taken to assure an accurate blood glucose level from a 
metabolic laboratory (BMP) or arterial blood gas panel before initiating any insulin therapy, inc luding sliding 
scale or scheduled insulin.  
All study sites not using the StatStrip POC glucometer should follow these guidelines:  
Guidance for blood glucose monitoring in patients enrolled this study: 
 
CITRIS Protocol Version  9 
 23 • Critical care Nursing and Physician leadership at all s tudy sites must be informed of vitamin C’s effect 
on point of care (glucometer) blood glucose and arterial blood gas glucose point of care values. 
• In-service training  will be documented in the Study Training Log 
• Bold signage will be displayed on all study instructions, data collection forms, and at the patient’s head 
of bed, stating: 
 STOP! Do not use Accuchek or other Point of Care devices to measure glucose on this patient  
 Use only metabolic or gas lab glucose screening methods 
 This patient is enrolled in  a study with Vitamin C, which artefactually increases POC glucose 
testing  
 Do Not Initiate or Utilize Sliding Scale, Scheduled Insulin, or Continuous Insulin 
Infusion  Without Laboratory Confirmation of Blood Glucose 
• Those receiving insulin infusion or sliding scale insulin will have metabolic glucose screening on the 
schedule determined by the primary physician and paid for by the study 
• Blood glucose monitoring for insulin administration guidance should only  be by a metabolic or blood 
gas laboratory measured blood glucose results, whether or not the study patient is receiving insulin  
• Study personnel will follow each study patient closely to monitor insulin use to ensure that point of 
care glucose screening is suspended for the research subject.  
• If subject loses central venous access (PICC line and arterial line acceptable), Vitamin C infusions are 
to stop but subject not withdrawn.  Data collected through end of study. 
• Point of care glucose testing may resume 36 hours after the last infusion of study drug. 
4. Study  Population and Enrollment  
4.1. Number/Source/Screening  
 
The trial will accrue a maxi mum of 170 patients ov er a 2-3 year period. Patients with sepsis associated  ALI 
will be recruited from  intensiv e car e units at Virginia Commonwealth University Health System, Medical 
College of Wisconsin and sub- site, Aurora St. Luke’s Medical Center, The Cleveland Clinic Health System  
and its sub- site, Fairview Hospital.  Study personnel will review patients within  inten sive c are units daily to 
identify potential candidate s for enrollment. Permission to approach patients and/or their fami lies will be 
requested from the atten ding physicians in charge of patient care in the ICU . All patients meeting t he 
inclusion/exclusion  criteria will be  approached with a consent and will be entered into a screening log. If the 
patie nt is n ot enrolled, th e screening log will in clude information explaining why enrollment did not occur 
(exclusion criteria, att ending physician denial, patient refusal, etc.).   
 
Patients will be documented in the Study Screening Log when all Inclusion Criteria are met.  A Screen Failure is defined as a patient meeting all Inclusion Criteria but not meeting Exclusion Criteria.  
 
4.2. Inclusion Crite ria 
4.2.1 CITRIS -ALI Inclusion Criteria:  
CITRIS -ALI Inclusion  Criteria:  
Patients must have suspected or proven infection, and meet 2 out of 4 of the criteria for Systemic Inflammatory Response (SIRS) due to infection, and be accompanied by at least 1 criterion for sepsis associated  organ 
dysfunction,  and meet all 5 criteria for Acute Respiratory Distress Syndrome (ARDS).  
 
CITRIS Protocol Version  9 
 24 1. Suspected or proven infection : (e.g., thorax, urinary tract, abdomen, skin, sinuses, central venous 
catheters, and central nervous system, see Appendix A).  
2. The presence of a systemic inflammatory response: Defi ned as: fever:  >38ºC (any route) or 
hypothermia:  <36ºC (core temp only), tachycardia:  heart rate > 90 beats/min or receiving medications 
that slow heart rate or paced rhythm, leukocytosis :  >12,000 WBC/µL or leukopenia:  <4,000 WBC/µL 
or >10% band forms.  Respiratory rate > 20 breaths per minute or PaCO2 < 32 or  invasive mechanical 
ventilation. 
3. The presence of sepsis associated  organ dysfunction:  (any of the following thought to be due to 
infection) 
a. Sepsis associated  hypotension (systolic blood pressure (SBP) < 90 mm Hg or an SBP decrease > 
40 mm Hg unexplained by other causes or use of vasopressors for blood pressure support (epinephrine, norepinephrine, dopamine =/> 5mcg, phenylephrine, vasopressin)  
b. Arterial hypoxem ia (PaO
2/FiO 2 < 300) or supplemental O2 > 6LPM. 
c. Lactate > upper limits of normal laboratory results  
d. Urine output < 0.5 ml/kg/hour for > two hours despite adequate fluid resuscitation  
e. Platelet count < 100,000 per mcL  
f. Coagulopathy (INR > 1.5)  
g. Bilirubin > 2 m g/dL  
h. Glasgow Coma Scale < 11 or a positive CAM ICU score  
4. ARDS characterized by all the following criteria  
a. Lung injury of acute onset, within 1 week of an apparent clinical insult and with progression of respiratory symptoms  
b. Bilateral opacities on chest imaging not explained by other pulmonary pathology (e.g. pleural 
effusions, lung collapse, or nodules) 
c. Respiratory failure not explained by heart failure or volume overload 
d. Decreased arterial P aO2/FiO2 ratio ≤ 300 mm Hg 
e. Minimum PEEP of 5 cmH
2O  
 
CITRIS -ALI Exclusion Criteria:  
1. Known allergy to Vitamin C 
2. inability to obtain consent;  
3. age < 18 years;  
4. Not on a ventilator 
5. No indwelling venous or arterial catheter in patients requiring insulin in a manner that requires glucose 
being checked more than twice daily (e.g. continuous infusion, sliding scale)  
6. Presence of diabetic ketoacidosis  
7. more than 48 hrs since meeting ARDS  criteria;  
8. patient or surrogate or physician not committed to full support (not excluded if patient would receive all supportive care except for cardiac resuscitation);  
9. pregnancy or breast feeding, 
10. moribund patient not expected to survive 24 hours; 
11. home mech anical ventilation (via tracheotomy or noninvasive) except for CPAP/BIPAP used only for 
sleep -disordered breathing; 
12. on home O2  > 2LPM , except for with CPAP/BIPAP  
13. diffuse alveolar hemorrhage (vasculitis); 
14. interstitial lung disease requiring continuous home oxygen therapy; 
 
CITRIS Protocol Version  9 
 25 15. Active kidney stone 
16. Non English speaking; 
17. Ward of the state (inmate, other)  
 
4.3. Enrollment, Ran domi zation, and Study Initiation Time Window  
 
All ALI criteria (4.2.3  a-d above) must occur within the same 24-hour period. The onset of ALI is when the 
last criterion is met.  Patients must be consented  within 48 hours of ALI onset.  SIRS criteria must occur 
within  the 48 hours before and 24 hours after ALI onset. Information for determining when these tim e 
window criteria were met may co me from either the study hospital or a referring hospital report.  
Randomization must occur within the same 48 hours of ALI onset, as is for consent.  Dose 1 must be 
administered within 6 hours of randomization.  Following randomization, the low tidal volum e prot ocol for 
mechanical ventilation  (Appendix C) and the fluid m anag ement strategy  protocol (Appendix D) may be 
initiated within one and four hours respectively (if not already being utilized) , if clinically indicated . 
 
4.4. Informed Consent  
 
Informed consent will be obtained from each patient or surrogate (family or legal representative) before 
enrollment in the trial. No study procedures will be conducted before obtaining informed consent. 
 
4.5. Randomization  
 
After in formed consent is given, a randomized a ssign ment will be made by the Investigational 
Pharmacy  of the Lead Site and Coordinating Center (VCUHS) to admi nister eith er Vitamin C  therapy or 
placebo. Each participating pharmacy will have a pre-defined 
randomization chart by which to determine whether to administer the study drug or placebo to each particular subject. The random ization will be stratified by institu tion to 
one of the two study arm s. 
 
4.7. Minorities and Women  
 
 The demographic profiles of the Ce nters selected for the study 
show that the aggregate patie nt population contains represen tative 
proportio ns of minorities and wom en (Table 1). Recruit ment of 
minorities and wom en will be monitored by th e Study Coordinating 
Center.  If necessary, a dditio nal recruitment ef forts will be  made at speci fic cen ters to ensure th at the 
aggregate patient sample contains appropriate gender and minority subs ets. Pregnant wo men will be excluded 
becau se of the lack  of safety data for infused Vitamin C use during pregnancy. 
5. Study  Procedures 
 
If a pregnancy test  is not available before i nformed consent, blood or urine tests will be obtained after 
informed consent but before randomi zation to ensure e ligibility. Patie nts excluded on the basis of tests 

 
CITRIS Protocol Version  9 
 26 obtained in this manner will not be included in the study. 
 
5.1. Vitamin C or Pl acebo Administration  
 
All study drug doses will b e administered via central or peripheral line infusion. Should no central or 
peripheral line be available at scheduled time of infusion, a call should be placed to pharmacy to 
determine if study drug may be piggybacked into the line that  is infusing a different drug.  If 
administering study drug via piggyback is contraindicated then study drug infusion may be delayed by a maximum of 6 hours. If clinical drug administration schedule is such that study drug will not have an available administration time beyond this delay, a dedicated new line (peripheral or centra l) should be 
inserted. Study drug will be b linded using an identical appearing pl acebo.    
 
The prepared IV bags will have the IV tubing attached and primed by the study pharmacist.  Amber shrouding will be used to cover the IV bag and the IV tubing in order to maintain the blind.  The product labeling will be blinded as to what the actual product is.  For example, the drug name and dose will be indicated as per the following:  "Ascorbic acid ____mg or placebo in 50cc D5W".   
1. First study drug do se (L-ascorbic acid or place bo) will be considered “Dose 1” and will be 
administered within 6 hours of random ization or the earliest available time post any clinically indicated 
procedure which requires the patient to be off the unit. All doses will be administered in the ICU.  Patients receiving vitamin C will receive 25% of the total daily calculated dosing (200mg/kg/24 hours) and will be infused over 30 minutes for this first dosing. 
2. Subsequent doses  which represent 25% of the day’s total dose will be infu sed every six hours through 
96 hours (+/- 3 hours).  
a. Timing of Dose 2 will be triggered by the physician order for q 6 hour administration and will therefore be listed on the bedside MAR.  As such, timing of Dose 2 may be out of the +/- 3 hour window and will not trigger a protocol deviation.  
b. If for any reason any other m aintenance dose is not ad ministered within window, the dose will 
be skipped and the next scheduled dose will be given and documented in the data collection tool.  
 
5.2. Drug Level Specimen s (venous blood)  
 
Preliminary studies performed during the phase I trial showed that an every 6 hour infusion protocol resulted in steady state plasma levels after 18 hours. In this phase II trial, p lasma levels of Vitamin C  will be 
obtained to determine the relations hip, if any, of plasm a levels to either t he plei otropic effects or t he 
toxicities of Vitamin C  or to biomarker levels .  
5.3. Completion of Study Drug Administration  
 
Completion  of study drug administration: Study drug administration will be stopped when one of the 
following conditions is met, whichever co mes first:  
1. Final drug dose at 96 hours or discharge from ICU, whichever comes first. 
2. Discharge from  study hospital 
3. Loss of indwelling venous or arterial catheter with no in tent to replace the line , making it impossible to 
monitor glucose levels via central laboratory without multiple peripheral sticks.   
 
CITRIS Protocol Version  9 
 27 4. Withdrawal from study  
5. Death  
 
Note:  If a patie nt is read mitted to the ICU after study drug has already been st opped per protocol, it d oes 
NOT get restarted when read mitted to the ICU.  
5.4. Premature Withdrawal from Treatment 
 
Loss of indwelling venous or arterial catheter will trigger the stopping of Vitamin C infusions but subjects will 
remain on study.  Blood glucose moni toring will continue via the central laboratory for 36 hours after the last 
infusion via peripheral IV draws or peripheral sticks.  Biomarker sampling via peripheral IV and/or peripheral stick is  allowable as it occurs only 4 times throughout the study and likely only once (if at all) after the patient 
has been discharged from the unit and is without a central line. 
 
The study drug will be di scontinu ed if a patient develops a metabolic acidosis unexplained by other 
etiologies (lactic acidosis secondary to septic shock). Determination of the presence of metabolic acidosis 
will be made by the site investigator.  Study drug will also be discontinued if prim ary care team or surro gate 
decision m aker request withdrawal. Data co llection will co ntinue on these patients following withdraw al of 
study drug.  
Requests to unblind a patient's study treatment can be made to the study (investigational) pharmacist.  Unblinding study treatment should occur only in the case of an emergency  when knowledge of the study 
treatment is essential for subject care to treat a serious adverse event and prevent further harm or death.  
If possible, a decision to unblind should be discussed with the Principal Investigator or a sub- Investigator prior  
to unblinding the study treatment.  
If a blind is broken (either intentionally or unintentionally) , the circumstances should be documented as 
to who, what, when, and why and all documentation shall be kept by the study pharmacist. 
 
5.5. Ventilator Procedures  
 
Ventilator  management, including weaning, will follow the modified ARDS Network lower tidal volume (6 
ml/kg PBW) protocol (Appendix C).liii  If not already being utilized, th is low tidal volu me protocol for 
mechanical ventilation will be initiated within one hour of random ization , if possible . Since the ti me a patient 
achiev es unassisted ventilation affects the secondary endpoint of ventilator free days ( VFDs ), and because 
recen t evidence -based consensus rec ommendations have identified a best practice for weaning, weaning 
strategy will also be contr olled by p rotocol ru les in accordan ce with these evidence -based recommendatio ns. 
This will ass ure similar weaning methods.  This new er weaning strategy is a si mplified version of the 
weaning strategy used in pr ior ARDS Network stud y protocols (see Appendix C ). 
 
5.6. On-Study Fluid Management  
 
Fluid  management during shock will not be pres cribed  per study protocol. In subjects who are not in shock, a 
conserv ative fluid managem ent approach will be administered, if possible . This conservative fl uid 
management approach will repres ent a si mplification of the algorithm utilized in th e ARDS Network FACTT 
study (see Appendix D ).liv  If not already being utilized, th is conservative fluid management approach will be 
initiated , if possible, within four hours of randomization and continued until the subject has reached un assisted 
 
CITRIS Protocol Version  9 
 28 breathing (UAB) or study hour 168, whichever occurs first.  
6. Data  Collection  
 
6.1. Backgrou nd Assessments  
 
1. Demographic :  
a. Gender 
b. Age 
c. Race/ Ethnicity  
2. Insurance status  
a. Privately insured  
b. Medicaid  
c. Medicare  
d. Other public 
e. uninsured  
 
3. Pertinent Medical History and Physical Exa mination  
a. Etiology of Sepsis  
b. diabetic status – Hx of Diabetes Yes No  
i. Insulin received?   Yes No 
c. patient place of residence: Home independently, home with help (supervision, direction, personal 
assistance), home with professional help (nursing/nursing service), intermediate care or rehab facility, skilled nursing facility, other (specify) 
d. Patient admitte d directly from: OR, Recovery Room, ER, Floor, another special care unit, 
another hospital, direct admit, step-down unit 
e. Hx of alcohol use via  the AUDIT -C Questionnaire:  
i. How often do you have a drink containing alcohol?  
Never  
Monthly or less  
2-4 times per month  
2-3 times per week  
4 or more times per week  
ii. How many standard drinks containing alcohol do have on a typical day?  
1 or 2  
3 or 4  
5 or 6  
7 to 9  
10 or more  
iii. How often do you have six or more drinks on one occasion?  
Never  
Less then monthly  
Monthly 
Weekly  

 
CITRIS Protocol Version  9 
 29 Daily or almost daily  
 
4. Study enrollment date   
5. Acute or Chronic renal failure and use of dialysis  
6.2. Baseline/Hour 0  Assessments  and Procedures  
 
The following inform ation  will be recorded during the 24 hour interval preceding random ization. If more than 
one value is a vailable for this 24 hour period, th e value closest to the ti me of random ization will be recorded. If 
no values are available fr om the 24 hours prio r to rando mization, then values will b e measured po st 
randomization bu t prior to initiation of study drug. 
 
Vital Signs: Blood Pressure ( BP), Heart Rate ( HR), Mean Arterial Pressure ( MAP ), Respiratory Rate 
(RR), Temp erature ., O 2 saturations , Central Venous Pressure (CVP ), Body weight, Glascow Coma 
Score  
Suspected or known site of sepsis 
SOFA  Score  
VE40 = [Minute Ventilation ÷ Weight (kg)] x [PaCO 2 ÷ 40] – closest one to time of randomization 
Oxygenation Index = [F iO2 x Mean Airway Pressure] ÷ PaO 2 
Ventilator Data: tidal volume, Fi O2, PEEP, inspirat ory plateau pre ssure, Peak Inspiratory 
Pressure, and mean airway pressures.  
Arterial Blood Gasses: Pa O2, PaCO 2, pH, HCO3  and SpO 2 
Serum  Sodium, Potassium, Metabolic Glucose, BUN, Creatinine, Billirubin Total, WBC, Hgb, Hct, 
Platelets, PT/INR  
Vasopressors or inotropes (epinephrine, norepinephrine, phenylephrine, vasopressin, dopamine) 
Insulin received?   Yes No 
In/Out – total – for first 7 days  or for every day in  ICU, whichever is shorter  
In/Out – Urine - for first 7 days or for every day in ICU, whichever is shorter 
Concomitant Medications: use of steroids 
Blood for biomarkers  will equal approximately 12ml. Blood sam ples will be processed and 
divided per the Laboratory Instructions Manual  
 
6.3. Assessments after Enrollment 
 
The following data will provide t he basis for assessing protocol co mpliance and safety as well as between -
group differences in sev eral efficacy variable s.  Data for each of the variables will be recor ded on the days 
shown in the Time- Even ts schedule (Appendix E) or until d eath or dischar ge from the intensive care uni t. 
 
 
Hours:  
 Required:  
 
Q 24 hours for as 
long as patient is in 
ICU or 7 days 
(whichever comes 
first I/O Total  
I/O Urine  
Insulin Receipt 
0, 48, 96, 168   VS, SOFA, ABGs, Routine Labs, Con Meds, AE/SAE Assessments, Blood draw for 

 
CITRIS Protocol Version  9 
 30 Biomarkers , Insulin Receipt  
 
As Available:  
VE40, OI, Weight, Bilirubin, Ventilator Data, known site of sepsis  
28 Days  Required : 
Ventilator Free Days to Day 28, All- Cause Mortality to Day 28, ICU Free Days to 
Day 28  
Use of dialysis  
60 Days  Hospital Free Days at Day 60  
 
 
Reference Measurements 
All data collected below will occur at the following timepoints: hour 0 (collected within the 24 hours prior to 
randomization, or post randomization, but pre-infusion), hour 48 (a timepoint prior to infusion 9), 96 (a 
timepoint close to hour 96 and after infusion 16), hour 168 (a  timepoint close to hour 168) 
 
1. Ventilator Data  - The following conditions will be ensured prio r to measurements:  no endobronchia l 
suctioning for 10 minutes; no invasive procedures or ventila tor changes for 30 minutes. 
2. Arterial Blood Gas es when Arterial line is in place for clinical reasons  
3. Vital Signs  
4. Labs  
5. Vasopressor   
6. Use of Steroids 
7. Blood samples for biomarkers .  
 
Blood specimens will be batch -sent to the VCU Centr al Repository to be stored. Specimens will be identified 
by a unique number.  All d ata released by the C linical Coordinating C enter  for studies will be linked to the 
speci men but will be de- identified. Plasma collected  for this tria l will be frozen and sto red at the VCU bio-
repository for future research. 
7. Statistical Considerations  
 
7.1. Statistical Methods 
 
CITRIS -ALI Data Analysis Plan : We plan to enroll 170 patients in the CITRIS-ALI study (85 per 
group) to allow for the possibility of approximately 10% dropouts. The projected sample size for this study 
should provide adequate power to detect meaningful differences between the study groups over time. All tests will be two -sided at the α = .05 level of significance. Effects will be reported with a point estimate and 95% 
confidence intervals in addition to p- values. We will examine the distributions of all measures and identi fy 
possible outliers; outliers will be thoroughly checked for collection or data entry errors before being used in the analysis. All hypotheses will be tested and data analysis will be done using a variety of statistical methods with the most common method expected to be a Mixed Linear Model  (MLM) for continuous repeated measures. To 
assess the effect of the treatment on continuous outcome measures that repeat over time the MLM
lv,lvi will be 
used to fit a series of repeated measures ANOVA (RMANOVA) models. These models will have one between subject factor (Group; Placebo, Hi-VitC), one within subject factor (Time; Baseline, 12 hours, 24 hours, 36 hours, 48 hours, 72 hours, 96 hours, 7 days) and the interaction between “Group and Time.” The Group by 
 
CITRIS Protocol Version  9 
 31 Time interaction term will allow us to test the hypothesis that the difference between the treatment groups is the 
same over time. The MLM that will be used for these analyses differs from t he usual general linear model (i.e. 
ANOVA) in two ways. The MLM allows for the inclusion of both fixed and random effects at the same time and thus allows for the complete analysis of repeated measures designs. Second, observations in the MLM are not requi red to be independent, as is the case with ANOVA, so that correlated observations that arise from 
repeated measurements made on the same subjects can be accommodated. For the repeated within subjects measures, a variety of variance- covariance structures wi ll be evaluated to determine which provides the best fit 
to the observed data. Further, MLMs do not require complete repeated measurements data on all subjects when used to estimate the course of the outcome variable over time. Incomplete or missing data a re handled by the 
model, providing that the missing data are assumed to be “missing at random.”
lvii While it is expected that the 
randomization process will prevent any group differences with respect to factors that could impact the outcome measures we can also fit models that include these measures as additional covariates to determine whether any Group by Time  interactions remain significant.  Early Stopping : An early stopping determination will be made 
by the Data Safety Monitoring Board 
Power Estimates Samp le Size Calculation : The primary goal of this study is to examine the efficacy of 
vitamin C infusion on organ failure and selected biomarkers. We have chosen the co- primary variables of (1) 
SOFA score, (2) plasma c-reactive protein and (3) thrombomodulin. The sample size for the proposed study was calculated using observed organ failure data and the biomarker analyses from the phase I clinical trial at VCU. Using data from two biomarkers and the SOFA scores, a power/sample size calculation was conducted. Using the RMANOVA model and assuming an alpha level of 0.05, and using a Holm- Bonferroni correction to 
accommodate the multiple tests, the following table shows the required sample sizes to detect a significant Group by Time interaction effect at 96 hours. 
 
 
  
Subgroup Analyses from data at enrollment:  Shock presence or absence 
8. Data  Collection and Site Monitoring 
 
8.1. Data Collection  
 
Research  coordina tors will collect data and en ter it dire ctly into the web-b ased data en try sy stem managed by 
the Clin ical Coordinati ng Center and record on pa per data forms. Data will be trans ferred to the Clin ical 
Coordinating Center on a prescribed basis through a web -based data entry program. 
 
8.2. Site Monitoring  
 
Remote monitoring will be used and augmented with site visits performed by a contracted monitoring service 
to ensure that all regulatory require ments are met and to monitor the quality of the data co llected. Records of 
Institu tional Review Board approvals and pati ents’ c harts will be e xamined on a spot check basis to evaluate Power Estimates for a variety of samples sizes, α=0.05 significance level, for multiple 
primary endpoints using the Holm -Bonferroni Correction
Empirical Power
75/Group 80/Group 85/Group 90/Group 95/Group 100/Group
Co-Primary Variables: 
SOFA, CRP, TM77% 77% 80% 80% 82% 83%
 
CITRIS Protocol Version  9 
 32 the accuracy of t he data en tered into th e dat abase.  
 
9. Risk  Assessment  
 
9.1. Risks of Active Study Drug  
 
Intravenous Ascorbic Acid Infusion:  High dose ascorbic acid therapy is a powerful anti-oxidant and 
micronutrient and a safe therapy in normal subjects and in critically ill patients.lviii Muhlhofer and colleagues 
examined for the presence of adverse effects following intravenous infusion of 7500 mg Ascorbic Acid daily for 
6 days in normal subjects (n=6). No abnormalities in laboratory analysis (fasting state; hemoglobin, leukocytes, platelets, sodium, potassium, calcium, chloride, glucose, creatinine, urea, bilirubin, ALT, AST, ggGT, alkaline phosphatase, and prothrombin time were found. Nathens et al infused high dose ascorbic acid (1500 mg three times daily) into critically ill surgical patients for 28 days and found no serious adverse events.
lix Hoffer et al 
infused dosages as high as 1.5 grams/kg body weight three times weekly into patients with advanced cancer.lx  
Adverse events were infrequent consisting of nausea, vomiting, dizziness, and headache.  A systematic review conducted by Hans K. Biesalski 
lxion the safety of the long term low dose parenteral administration  of ascorbic 
acid in patients on haemodialysis revealed it to be safe with frequent monitoring of oxalate following dialysis.  Finally, in the safety study conducted here at VCU testing the safety of infusing high doses of ascorbic acid in patients with sepsis, in which approximately 8 of 24 subjects were receiving dialysis, no adverse events 
occurred that could be related to the ascorbic acid.  
 
Potential Physical Risks of Ascorbic Acid Infusion: As noted above, the risks associated with ascorbic acid 
infusion are few. Potential risks include: dry mouth, nausea, vomiting, dizziness, headache. 
 
Potential Psychological, Social, Legal Risks of Ascorbic Acid Infusion: No psychological, social or legal 
risks are identifiable from an exte nsive literature search.  The recently completed phase I trial: Vitamin C 
(Ascorbic Acid) Infusion in Human Sepsis where up to 16 grams of ascorbic acid was infused daily for 4 
days identified  no further risk that that identified.  
 
9.2. Risks of Blood Dra ws 
 
All patients will have blood drawn for resear ch purposes. Most blood will be drawn through indwelling 
catheters. Risks of drawing blood percutaneously are uncommon and include bleeding and bruising. 
 
9.3. Minimiz ation of Risks  
 
Federal  regulations at 45 CFR 46.111(a) (1) requires that ris ks to subjects are minimized by 
using procedures which are consistent with sound research design.  There are several ele ments of study design 
in the present protocol that meets this hu man subject protection requirement.  
 
Exclusion cr iteria prohib it particip ation of patients who mi ght be at increased risk from  the effects Vitamin C.  
Additionally, no adverse events occurred during the pilot study found to be related to the study drug.  Finally, 
vigilant clinical monitoring is standard of care for ICU patients.  
 
 
CITRIS Protocol Version  9 
 33 9.4. Potential Benefits  
 
Most  observational studies suggest a mortality benefit from  prior or in-patient Vitamin C  use after 
hospita lization f or serio us infections.  None of the observational trials have reported significant Vitamin C -
related toxicity.  An ani mal model of acute lung injury with intravenous LPS and feces induced peritonitis 
demons trate significantly less lung injury with Vitamin C , which m ay result  in shortening the tim e patients 
require mechanical ventilation. 
 
9.5. Risks versus Benefits  
 
The identifiable risks arising from exposure to intravenous ascorbic acid infusion are low. In our preliminary 
data, we extensively outlined the potential benefits brought by attenuation of acute lung injury and organ failure 
associated with bacterial sepsis. Given the low risk associated with ascorbic acid infusion and the potential high 
likelihood of benefit we assess the risk/benefit ratio to be low (i.e., that benefit far outweighs risk). 
 
10. Human Subjects  
 
Each  study participant or a legally  authorized representative must sign and date an informed consent form .  
Institu tional re view board approval will be required before any subje ct is ent ered into the study. 
 
10.1. Selection of Subjects  
 
Screening for patients to be enrolled in the CITRIS- ALI trial will occur in the ICUs at VCU Health System , 
The Medical College of Wisconsin  and sub- site, Aurora St. Luke’s Medical Center , The Cleveland Clinic  and 
its sub -site, Fairview Hospital .   
10.1.1. Equitable Selection of Sub jects  
 
Federal  regulations at 45 CFR 46(a)(3) require the equitable selection of  subjects.   The ICUs will be 
screened to dete rmine if  any patient m eets the i nclusion and excl usion c riteria. Data th at have been collected 
as part of the routine management of the subject will be reviewed to deter mine eligibility.  No protocol-
specific tests or proced ures will be performed as part of  the screening process.  If any subjects meet criteria 
for study enrollment, then the attending physician will be asked for permission to approach the patient or 
his/her surrogate for inform ed consent.  Justifications of  exclusion criteria are given in Section 4.3. These 
exclusion criteria neither unjustly exc lude classes of individuals from participation in the re search n or 
unjustly include classes of individuals from particip ation in the res earch.  Hence, the recruitm ent of subjects 
conforms to the princi ple of distributive justice.  
 
10.1.2. Vulnerable Subjects  
 
The presen t research aims to inve stigate the safety  and efficacy of a type of treat ment for patie nts with ALI 
and ARDS  secondary to severe sepsis.  No vulnerable subjects will be entered into this phase II trial . 
 
 
CITRIS Protocol Version  9 
 34 10.2. Informed Consent  
 
Federal  regulations 45 CFR 46.111(a)(5) require that informed consent will be sough t from  each prospective 
subject or the subjec t’s legally auth orized rep resentative.  The inves tigator is responsible for ensuring that the 
patient  or patient’s legal representative  understands the risks and be nefits of participating in the study, and 
answering any questions the patient may have throughout the study and sharing any new information in a 
timely m anner that may be relevant to the patient’s or the legal representative’s willingness  to continue his or 
her participation in the tria l. All study participants or the ir surrogates will be info rmed of the obje ctives of  
the st udy and the p otential ris ks.  The informed consent docum ent will be u sed to explain the risks and 
benefits of study participation to the patient in simple terms before the patient is entered into the study, and to 
document that the patient is sat isfied with his or her understanding of the risks and benefits of participating in 
the study and desires to participate in the study.  The investigator is responsible for en suring that in formed 
consent is given by each patient or legal representative. This includes o btaining the appropriate signatures 
and dates on the informed consent docum ent prior to the perform ance o f any protocol procedures and prior to 
the ad ministration of study agent. 
 
 
10.3. Identification of Surrogates  
 
Many  of the patie nts approached f or particip ation in this re search proto col will have li mitations of  decision-
making abilities d ue to their critical illness. Hen ce, most patie nts will not be able to provide informed 
consent.  Accordingly, informed consent will be sought from the potential subje ct’s le gally a uthorized 
representative.  
 
Regarding proxy consent, the existing federal research regulations (‘th e Com mon Rule’) state at  
45 CFR 46.116 that: “no investigator may involve a human being as a subject in  research…unless the 
investigator has obtained the legally effective  informed consent of the subject or the subject’s legally 
authorized representative” ; and defines at 45 CFR 46 102 (c) a legally authorized representative (LAR) as: “an 
individual or judicial or  other body authorized under applicable law to consent on behalf of a prosp ective 
subject to t he subject’s particip ation in th e pro cedures(s) involved in the research.”   OHRP d efined examples 
of “applicable law” as being state statutes, regulations, case law, or fo rmal opinion of a State Attorney G eneral 
that addresses the issue of  surrogate consent to medical procedures.  Such “applicable law” could then be 
considered as empowering the surrogate to provide consent for subject participation in the research. 
Interpre tation of “applic able law” is therefore state specific and hence, will be left to the discretion of  the 
individual I RBs of the respective clinical centers involved in the CITRIS -ALI trial. 
 
According to a previous President’s Bioethic s Com mittee (N ation al Bio ethics Adviso ry Com mittee),  an 
investigator should accept as an LAR…a relativ e or friend of the potential subject  who is recognized as an 
LAR for purpos es of clinical decis ion making under the law of the state w here the research ta kes 
place .
lxiiilxii Finally, OHRP h as opined in their deter mination letters  that a surrogate could ser ve as a LAR for 
research decision making if such an individual is authorized under applicable state law to provide consent 
for the “proced ures” inv olved in the research study.  
 
10.4. Justification of Surrogate Consent 
 
According to the Belm ont Report, r espect for persons incorpo rates at leas t two ethical convictions; first, that 
individuals should be treated as autonomous agents, and second, that persons with diminished autonom y are 
entitled to protection. One method that serves to protect subjects is restrictions on the  participation of 
 
CITRIS Protocol Version  9 
 35 subjects i n research that presents more than minim al risks. Com mentators and Research Ethics Com mission 
have held the view that it is perm issible to include incapable subjects in research that involves more than 
minim al risk as long as there is the potential for  beneficial effects and if the research presents a balance of 
risks and expected direct benefits similar to that available in the clinical setting.lxiv  Several  U.S. task forces 
have deem ed it is perm issible to include  incapable subjects in research.  For example, the Am erican College 
of Physicians’ docum ent all ows surrogates to consent to research  involving incapab le subjects only “ if the 
net additional ris ks of parti cipation a re not substantia lly greater than the risks of standard treatment .”lxv   
Finally,  the National Bioet hics Ad visory Committee (NBAC)  stated “that an IRB may approve a protocol 
that presents greater than minimal risk but offers  the prospect of direct m edical benefits to the subject, 
provi ded that…the potential subject’s LAR gives perm ission…” 
 
Consisten t with the ab ove eth ical se nsibilities re garding the  particip ation of decision ally incapa ble subjects in 
research and t he previous assessm ent of risks and benefits in the previous section, the present trial presents a 
balance of  risks and potential dir ect benefits that is similar  to that available in the clinical setting,  with the 
exception of the additional blood draws. 
 
10.5. Additional Safeguards for Vulnerable S ubjects  
 
The present research will not involve subjects who might be vulnerable to coercion or undue influence.  
 
10.6. Confidentiality  
 
Federal  regulations at 45 CFR 46 111 (a) (7 ) requires that when appropriate, there are adequate provisions 
to protect the privacy of subjects and to maintain the conf identiality of  data. To maintain confidentia lity, all 
laboratory specim ens, evalu ation forms, and reports will be identified only by a coded number.  The coded 
number will be generated at random  by a co mputer, and only the study invest igators will have access to the 
codes. All rec ords will be ke pt in a locked, password protected computer. All computer entry and 
netw orking progr ams will be done with coded numbers only. All paper case report for ms will be maintained 
in a locked cabinet inside a locked o ffice. Clinical infor mation will not be released without the written 
perm ission of the patient, except as necessary for monitoring by the National Heart, Lung, and Blood 
Institute, the Federal Drug Admi nistration or other authorized Federal Agencies. 
 
11. Adverse Event Reporting /Safety Reporting 
Investigat ors will d etermine daily if  any clin ical adverse ex periences occ ur during t he period from informed 
consent through study hour 168 and will be followed up through resolution, resolved with sequelae, 
unresolvable or death.    
It is expected that Diseases/Illnesses/Symptoms associated with the SEPSIS ALI study population will occur 
in the study population, independent of investigation product exposure.  These associated 
diseases/illnesses/symptoms will be considered  as part of the study inclusion processes and/or study 
assessments and as such will not be considered ‘reportable’ Adverse Events (AE)/Serious Adverse Events (SAE) unless the Investigator has a reasonable doubt regarding the relatedness of the event to the investigational product.  
 
CITRIS Protocol Version  9 
 36  
The investigat or will evaluate any chan ges in laboratory values and physical signs and will determ ine if the 
change is clinically i mportant and different from what is expected in the course of treatment of patient s with 
ALI.  If clinically  important and un expected ad verse ex periences occur, t hey will be reco rded on the a dverse 
event case report form. 
 
 The following will be considered re portable  adverse ev ents: 
 For this trial, a report able advers e event is defined as:  
 
1. Any clinically important untoward medical occurrence in a patient receiving study drug or 
undergoing study procedures which is  different from  what is expected in the clinical course of a 
patient with severe sepsis associated ALI, or, 
2. Any clinically important, untoward medical occurrence that is thought to be associated w ith the 
study drug or procedures, regardless of the “expectedness” of the event for the course of a patient with severe sepsis associated  ALI.  
    3. Investigat ors will repor t all serious,  unexpected, AND  study- related adver se events from the time 
of informed consent through study hour 168 that are considered to be harmful and unintended responses to the investigational product and/or study related procedures in the participan ts’ case 
report forms. ‘Responses to investigational product’ means that the causal relationship between an investigational product and an adverse event cannot be ruled out.   
 
Expected  Events For ALI considered unreportable:  refer to Appendix F Table  
1. Defined as: Untoward clin ical occurre nces perceived by the investigator to occur with 
reasonable frequency in the day to day care of patients with ALI treated in an intensive care 
unit with mechanical ventilation.                                   
2. Examples of untoward clinical occurrences that are expected in the course of ALI include: 1) 
transient hypoxemi a, 2) agitation, 3) deliriu m, 4) nosocomial infections, 5) skin breakdown, 
and 6) gastrointestinal bleeding. Such events, which are often the focus of prevention efforts as part of usual ICU care, will not be co nsidered reportable adver se events u nless the event is 
considered by the investigator to be associated with the study drug or procedures, or unexpectedly severe or frequent for an individual patient with ALI.  Examples of 
unexpectedly frequent untoward clinical occurrences would be repeated  episodes of 
unexplained hypoxemia. This would be in contrast to an isolated epis ode of transient 
hypoxemia (e.g., Sp0 2  ~85%) , related to p ositio ning or suctioning.  This latter even t would 
not be considered unexpected by nature, severity or frequency. 
3. Adverse events occurring from the time of informed consent through study hour 168 or until discharged from the hospital, withdrawal from the study or death, will not be considered ‘reportable’ Adverse Events (AE)/Serious Adverse Events (SAE) unless the Investigator has a reasonable doubt regarding the relatedness of the event to the investigational product.  
 
The following will be re ported as a dverse ev ents:  
 
Investigat ors will repor t all unanticipated problems  that involve risk or harm to a research participant  
AND was not anticipated or foreseen (e.g., not described in the consent form)  AND is probably or 
definitely related to or caused by the research , as defined in Appendix F, to the Da ta Coordinating Center 
by phone and email within 24 hours of becoming aware of event. The Institutional Review Board for the lead 
 
CITRIS Protocol Version  9 
 37 site will be notified within 5 business days of receiving notice of the unanticipated problem.  Participating 
sites shall report to their Institutional Review Board in accordance with their institution’s rules and 
regulations. 
 
The Data  Coordinating Center (VCU) will report all, unanticipated problems, defined as problems th at 
involve risk or harm to a research participant AND was not anticipated or foreseen (e.g., not described 
in the consent form)  AND is probably or definitely related to or caused by the research , to the DSMB  
within 7 calendar days of the CCC being notified of the event. The Data Coordinating Center will d istribute 
the written sum maries of th e DSMB’s periodic review s to participating centers.  
 
The Data  Coordinating Center will also determ ine if the serious ad verse event is unexpected for Vitamin C .  
Unexpected for Vitamin C  is defined  as any event n ot listed in th e Vitamin C  package insert. If the  Data  
Coordinating C enter det ermines that any serious and study- related adverse event is un expected f or Vitamin C , 
the FDA will be  notified within 7 calendar days. Such events m ay also meet the definition of Unanticipated 
Problems  as described below.  
 
Investigators m ust report Unanticipated Problems , regardless of severity, associated with the study drug or 
study procedures within 24 hours.  An unanticipated problem is defined as follows:  
 
Unanticipated Problem (UP) : any incident, experience, or outcom e that meets all of the following cr iteria 
will be reported from the time of consent through study hour 168 until resolved, withdrawn from the study, 
death occurs or lost to follow up: 
• Unexpected, in terms of nature, severity, or frequency, given the rese arch procedures that are 
described in the protocol- related docu ments, such as the IRB -approved research protocol and informed 
consent docum ent; and the characteristics of the su bject population being studie d; 
• Related  or possibly related to participation in the research, in this guidance document, possibly 
related means there is a reasonable possibility that  the inci dent, experien ce, or outcom e may have 
been caused by the procedures involved in the research; 
• Suggests that the research places su bjects or ot hers at a greater risk of harm (including physical, 
psychological, economic, or social harm) than was previously known or recognized.  
1. Safety Reporting : 
Investigator safety reports are prepared for suspected unanticipated serious adverse reactions according to local 
regulatory requirements and are forwarded to investigators as necessary.  An investigator who receives an 
investigator safety report describin g an SAE(s) or other specific safety information (e.g., summary or listing of 
SAEs) from the Clinical Coordinating Center will file it and will notify the IRB/IEC, if appropriate, according 
to local requirements.  
  
 
CITRIS Protocol Version  9 
 38 12. APPENDI CES 
 
 
APPENDIX A: Guidelines  for evidence  of infection  
 
1.  Infections of the thorax:  
a) Chest x -ray or CT scan showing a new or progressive infiltrate, consolidation, 
cavitation, collection, or pleural e ffusion, and a clinical presentation  consistent with 
pneumonia or empyema 
b) Pneu monia can be defin ed as the presence of  new in filtrat e (s), absen ce of a noninfectious 
explanation and either  signs of SIRS as per protocol or purulent sputum production with 
an identifiable pathogen. 
c) Aspiration Pneum onitis in the acute phase is n ot considered a n infection. 
d) However,  if SIRS persists > 24 hours after aspiration, then an infectious etiology can be 
presu med. 
2.  Abdominal infection: 
a) Perforated viscus or ische mic bowel with eith er locali zed per itonitis  
b) Peritoneal fluid with > 250 PMNs  
c) Clinic al signs of cholangitis or appen dicitis  
d) Clostridium di fficile to xin positiv e with evi dence of  colon dila tion 
e) Suspicion of peritonitis by clinical exa mination only 
3.  Skin or s oft tissue infe ction:  Acute onset infection of the skin, such as erysipelas, or 
infection involving deeper soft tissue 
4.  Bacterial  meningitis: cerebrospinal fluid analyses if available and a clinical presentation 
consistent with bacterial meningitis  
5.  Urinary Tract:  
a) Positive te st for granuloc yte esterase or nitrate in urine, or a p ositive culture  (defined as >1 05 
CFU/m L) 
b) Urinalysis with increased WBC count or positive Gram stain  
6.  Central Line infe ctions: 
a) Catheter -related blood stream  infections (CR -BSIs) are defined as bactere mia/fungemi a in a 
patient with an  intravascular  catheter  with at least one positi ve blood cultu re obtained from a 
peripher al vein, cli nical manifestations of infection (i.e., fever, chills, and/or hypotension), and 
no apparent source for the bloodstream infection except th e catheter. The catheter must be in 
place for at least 48 hours prior to development of the bloodstream infection. 
 
7.  Sinusitis  
a) Air fluid levels in sinus seen on CT scan  
** Use of antibiotics at ti me of consent (provided the antibiotics are not for prophylaxis) is considered 
evidence of suspected infection. Examples of prophylactic antibiotics include: pre -surgical incision, 
antibiotic for the prevention of pneum ocystis jiroveci (aka carinii), herpes si mplex, cytomegaloviryus, 
and latent mycobacterial disease.  
 
The follo wing are not considered evidence of infectio n: 
a) Fever of unknown origin 
b) Blood cultu res that are considered positive only because of the isolation of a likely 
contaminant organism 
 
CITRIS Protocol Version  9 
 39 c) Postoperative hypotension within 24 hours of incision and/or fever without a verified 
infectious focus.  
d) Leukocytosis alone in the presence of steroid usage is insufficient evidence of infection. 
e) Leukocytosis alone in the presence of connective tissue disorder is insufficient evidence of infection. 
  
 
CITRIS Protocol Version  9 
 40 APPENDIX B:  Pleiotropic Effects  of Vitamin C  
  
1.  Cell culture/in  vitro studies  
• Reduced hum an neutrophil  adhesion to endothelial cellslxvi 
• Protect s neutrophils against intracellular effects of superoxide generation.lxvii 
• Protects monocytes against oxidative damagelxviii 
• Reduced PMA induction of NF -κB 
• Protect s against oxidized -LDL -induced expression of MCP -1 in cultured human um bilical vein 
endothelial cellslxix 
• Modulates the inhibition of platelet aggregation by neutrophilslxx 
• Inhibits expression of platelet expression of CD40 ligand which promotes thrombosislxxi 
• Inhibits NADPH oxidase subunit p47phox expression in microvascular endotheliumlxxii 
• Influences dendritic cell function.lxxiii 
• Effects of vitamin C on intra  cytoplasmic cytokine production in human whole blood monocytes and 
lymphocytes. exposed to LPS or immune co mplexe slxxiv 
• Inhibition of  the induction of inducible nitric oxide sythetase (iNOS) and TNF -α, IL-1β  and IL -6 in 
astrocytes, microglia and macrophages stimulated with LPS or cytokines   
• Vitamin C inhibits NO -induced stabilization of HIF -1alpha in HUVECslxxv 
• Cobalt -induced oxidant stress in cultured endothelial cells: prevention by ascorbate in relation to HIF -
1alpha.lxxvi 
 
2.  Intact animal studies  
• Attenuates LPS induced acute lung injury.lxxvii  
• Attenuates lung injury in a cecal ligation and puncture model of peritonitis.lxxviii 
• Corrects capillary blood flow in septic skeletal musculature.lxxix 
• Inhibits iNOS expression in septic vasculature.lxxx 
• Attenuates iNOS expression in IFN gamma- stimulated rat skeletal muscle endothelial cellslxxxi 
• Attenuates hepatic fib rosis by upregulating peroxiso me proliferators-activated receptor-gammalxxxii 
• Inhibits both flow- and agonist-induced EDHF in the rat mesenterylxxxiii lxxxiv, 
• Multiple molecular transporters responsible for movement of ascorbate intracellularlxxxv 
• Attenuates peroxidative damage and tissue edema in ischemia/reperfused gut.lxxxvi 
• Ascorbate supplementation significantly decreases plasma IL -6 levels in an animal model of 
hemorrhagic shock.lxxxvii 
• Vitamin C deficiency causes the collagen -disassembly disease scurvy   
• Ascorbic acid prevents testosterone-induced hyperplasia of rat prostate by down-regulating HIF -
1alphalxxxviii 
• Plasma AA maintains the stability of “ acellular Hb ” susceptible to oxidationlxxxix 
• Endogenous ascorbate on oxidation, oxygenation, and toxicokinetics of cell- free modified 
hemoglobin after exchange transfusion in rat and guinea xc 
Human studies  
• Normalizes monocyte adhesion to endothelium in vitamin C deficient subjects. xci 
• Supplementation in chronic hemodialysis patients reduce lymphocyte 8- OHdG levels and 
intracellular ROS production xcii 
• Increase in muscle blood flow during dynamic exercise with acute A A administration in older 
adult humansxciii 
• Intravenous ascorbate improves outcomes during percutaneous myocardial interventionxciv 
• Plasma vitamin C level positively associated with serum pre-albumin levels and negatively 
associated with high sensitivity C-Reactive Protein  level s in patients with chronic renal 
 
CITRIS Protocol Version  9 
 41 failure .xcv,xcvi 
• Low plasma  ascorbate levels are associated with enhanced proinflammatory responses and 
impaired vascular function in lean and obese men.xcvii 
• Reduced inflammatory tissue damage in patients subjected to cardiac surgery with 
extracorporeal circulationxcviii 
• Ascorbate promotes iron utilization for erythropoiesis in patients with chronic renal failurexcix 
• High dose vitamin C infusion into surgically critically ill daily for 28 days attenuated the incidence of acute lung injuy/ARDS.
c 
  
 
CITRIS Protocol Version  9 
 42 APPENDIX C: Ventilator Procedures  
 
C.1. Ventilator Management  
 
A modified, simplified version of the ARDS Network lung protectiv e lower tidal volu me 
strategy  will be used in this trial.  This strat egy, which was associated with low m ortality rates in three  
previo us ARDS Network  trials  (ARMA, ALVEOLI, and FACTT), will ens ure that study subjects receive the 
beneficial  effects of lung protection while participating in this trial.ci cii The PI/PDs (Drs. Fowler, Truwit, 
Hite, Martin) and professionals at the CITRIS -ALI consortium medical centers have significant experience 
with the application of ARDS Network ventilation protocols . 
 
1. Any mode of  ventila tion capable of  delivering the prescribed tidal vo lume (V T, 6ml/kg predicted body 
weight, +/- 2ml/kg) may be used, provided the V T target  is monitor ed and adjusted appropriately. If 
airway pressure release ventilation (APRV) is used, tidal volu me is defined as the sum  of the volum e 
that results from  the ventilator pressure - release and an esti mation of the average spontaneous V T. 
2. VT Goal:  6 ml / kg predicted body weight.  
3. Predicted body weight (PBW ) is calculated from  age, gender, and hei ght (heel  to crown) 
a. accor ding to  the following equation s: 
b. Males: PBW (kg) = 50 + 2.3 [height (inches) – 60] 
c. Females:  PBW (kg) = 45.5 + 2.3 [height (inches) – 60] 
4. Measure an d record inspiratory plateau pressu re (Pplat) acc ording to ICU routin e (at least every four 
hours and after changes in V T and PEEP recommended) 
5. If Pplat > 30 cm  H2O, reduce VT to 5 ml/kg and then to 4 ml/kg PBW if necessary to  decrease Pplat to 
≤ 30 cm H2O. 
6. If VT < 6 ml/kg PBW and Pplat < 25 cm H 2O, raise V T by 1 ml/kg PBW to a m aximum  of 6 ml/kg. 
7. If “severe dyspnea" (more than 3 double breath s per minute or airway pressure rem ains at or below 
PEEP level during inspiration), then raise VT to 7 or 8 m l/kg PBW if Pplat re mains below 30 cm H 2O. 
If Pplat exceeds 30 cm H 2O with V T of 7 or 8 ml/kg PBW, then rev ert to lower VT and consider more 
sedation. 
8. If pH < 7.15, V T may be raised  and Pplat  limit suspended (not required).  
9. Oxygena tion target: [55 mm Hg <  PaO2  < 80 mm Hg ] or [88% < SpO 2  < 95%] .  When both Pa O2  
and SpO2 are available si multaneously, the PaO 2 criterion  will take preceden ce. 
10. Minimum PEEP = 5 cm H 2O 
11. Adjust F iO2 or PEEP upward within 5 mi nutes if there are co nsisten t measurements below the 
oxygenation target range 
12. Adjust F iO2 or PEEP downward within 30 minutes if there are consis tent measure ments above the 
oxygenation target range. 
13. There are no  requirements for m aintaining a specif ic PEEP to FiO2 ratio.  The lower PEEP/higher FiO2 
table  repre sents a consensus approach developed by ARDS Network investigators in 1995.  The higher 
PEEP/lower FiO2 table  (ALVEOLI) yielded equivalent results in a rando mized trial and would be 
acceptable and perhaps preferable in  patients  who appear to respond with a substa ntial increase in 
arterial oxygenation in the transition  from lower to higher PEE P. 
 
 
 
 
  
 
CITRIS Protocol Version  9 
 43 Lower PEEP/Higher FiO2 Treatm ent Group   
FiO2 .30 .40 .40 .50 .50 .60 .70 .70 .70 .80 .90 .90 .90 1.0 
PEEP  5 5 8 8 10 10 10 12 14 14 14 16 18 18-24 
 
Higher  PEEP/Lo wer FiO2 Study  Group  
 
FiO2 .30 .30 .30 .30 .30 .40 .40 .50 .50 .50 – .80 .80 .90 1.0 1.0 
PEEP  5 8 10 12 14 14 16 16 18 20 22 22 22 24 
 
Note:  Levels of PEEP in these FiO2/ PEEP tables  repre sent levels set on the ventilator, not levels of 
total- PEEP, auto- PEEP, or intrinsic -PEEP.  
 
14. No specific rules for respiratory rate. It is recom mended that the respiratory rate be increased 
in incre ments to a maximum set rate of 35 if pH < 7.30. 
15. No specific rules about I:E  ratio.  It is recom mended that duration of Inspiration be ≤ duration of 
Expiration. 
16. Bicarbonate is allowed (neither en couraged nor discouraged) if pH < 7.30. 
17. Changes in more than one ventilator setting driven by measurements of PaO2, pH, and Pplat may 
be performed simultaneously, if necessary.  
 
C.2. Weaning  
Com mencement of W eaning (applicable to patients ventilated invasively or non-invasively)  Patients 
will be assessed for the following weaning readiness criteria each day between 0600 and 1000. If a patient 
procedure, test, or other e xtenuating circum stance prevents assessm ent for  these  criteria between 06 :00 and 
10:00, then the a ssessment and initiation of subsequent weaning procedures may be delayed for up to six 
hours. 
 
1. At leas t 12 hours sinc e enrollment in the trial 
2. FiO2 ≤ 0.40 and PEEP ≤ 8 cm H2O or FiO2 ≤ 0.50 and PEEP = 5 cm H 2O 
3. Values of both PEEP and F iO2 ≤ values from previous day 
4. Not receiving neuromuscular blocking agen ts and without neurom uscular blockade  
5. Patient exhibiting inspiratory efforts. If no efforts are ev ident at bas eline, ventilato r set rate will 
be decreased to 50% of baseline level for up to 5 minutes to detect inspiratory effort s. 
6. Systolic arte rial press ure ≥ 90 mm Hg without vasopressor support (≤ 5 mcg/kg/min dopamine 
will not be con sidered a vasopresso r) 
 
Spontaneous  Breathing Trial Procedure and Assessm ent for Unassisted Breathing  
 
If criteria 1 -6 above are m et, then initiate a trial of up to 120 minutes of s pontaneous breathing 
with FIO2 < 0.5 using any of the following approaches: 
1. Pressure support (PS) < 5 cm  H2O, PEEP < 5 cm H 2O 
2. CPAP < 5 cm H 2O 
3. T-piece  
4. Tracheo stomy collar ( mask) 
 
The clinical team m ay decide to change mode dur ing sponta neous breathing (PS = 5, CPAP, 
 
CITRIS Protocol Version  9 
 44 tracheosto my mask, or T- piece) at any tim e during the spontaneous  breathing trial.  
 
Monitor for tole rance u sing the following: 
1. SpO 2  ≥ 90% and / or PaO 2  ≥ 60 mm Hg  
2. Mean spontaneous tidal volume ≥ 4 m l/kg PBW (if measured)  
3. Respiratory  Rate ≤ 35 / min 
4. pH ≥ 7.30 (if m easured)  
5. No respirat ory distress (defined as 2 or m ore of the following): 
a. Heart rate ≥ 120% of the 0600 rate ( ≤ 5 min at > 120% may be tolerated) 
b. Marked use of accessory  muscles  
c. Abdominal paradox 
d. Diaphoresis 
e. Marked su bjective dysp nea 
 
If any of the goals a-e are not met, revert to p revious ventilator settings or to PS greater than or equal to 
10 cm H 2O with Positive End -expiratory Pressure and F iO2 = previous settings and reassess for weaning 
the next morning.  The patient will be reassessed for weaning (Section C2) the following day. 
 
Decision  to re move ventilatory support: 
If tolerance criteria for spontaneous breathing trial (a -e above) are met for at least 30 minutes, the 
clinical team may decide to discontinue mechanical ventilation. However, the spontaneous breathing 
trial can continue f or up to120 minutes if to lerance remains in question. 
 
C.3. Definition of Unassisted Breathing  
1.  Spontaneously breathing with face mask, nasal pr ong oxygen, or room air, OR  
2.  T-tube breathing, OR 
3.  Tracheostomy collar (m ask) breathing, OR 
4.  CPAP ≤ 5 without PS or IMV assistance 5.  Use of CPAP or BIPAP solely for sleep apnea management 
 
C.4. Definition of Extu bation  
1.  Removal of an oral o r nasotrach eal tube 
2.  If a patie nt receives a tracheosto my, the time of extubation is defined as th e time when the patient 
achieves u nassisted breathing as defined in section C.3  
C.5. Completion of Ventilator Procedures  
 
Patients  will be considered to have completed the study ventilator procedures if any of the following 
conditions occur: 
 
1.  Death  
2.  Hospital discharge  
3.  Alive 28 days af ter enrollment 
 
If a pati
ent requires positive pressure ventilation after a p eriod of unassisted breathing, the study 
ventilator procedures will resu me unless the patient was dischar ged from the hospital or > 28 days 
 
CITRIS Protocol Version  9 
 45 elapsed since enroll ment. 
 
C.6. Removal from t he Ven tilator Management Protocol  
 
Patients  may be removed from the 6 ml/kg PBW tidal volume ventilation requirement if they develop 
neurologic conditions where hypercapnia would be contraindicated (e.g., intracranial bleeding, GCS < 8, 
cerebral edema, m ass effect  [midline shift on CT scan], papilledem a, intracranial pressure monitoring, 
fixed pupils). 
  
 
CITRIS Protocol Version  9 
 46 APPENDIX D: FACTT LITE Conservative Fluid  Management Approach 
If patient  does not have a MAP > 60mmHg and has not been off vasopressors for > 12 hours, then patient does 
not meet criteria for any actions prescribed in the Fluid Management Approach.  Document as “Not Clinically 
Indicated” .   
 
This fluid protocol captures the primary pos itive outcom e of the FACTT trial on increasing ventilator free 
days.  If clinically possible, for patients with a CVC, this protocol should be initiated within four hours of randomization in enrolled patients, and continued until UAB or study day 7, whichever occurs fi rst.  
o Discontinue maintenance fluids.  
o Continue medications and nutrition.  
o Manage electrolytes and blood products per usual practice.  
o For shock, use any combination of fluid boluses# and vasopressor(s) to achieve MAP ≥ 60 mmHg as fast as possible.  Wean vasopressors as quickly as 
tolerated beginning four hours after blood pressure has stabilized.  
o Withhold diuretic therapy in renal failure § and until 12 hours after last fluid bolus or  vasopressor given.  
 
   
 
  
 
  
 
 
 
  
 
 
   
 
  
 
  
 § Renal failure is defined as dialysis dependence, oliguria with serum creatinine > 3mg/dl, or oliguria with serum creatinine 0 -3 with  
   urinary indices indicative of acute renal failure.  
# Recommended fluid bolus= 15 mL / kg crystalloid (round to nearest 250 mL) or 1 Unit packed red cells or 25 grams albumin  
*Recommended Furosemide do sing = begin with 20 mg bolus or 3 mg / hr infusion or last known effective dose.  Double each subsequent dose until goal ach ieved 
(oliguria reversal or intravascular pressure target) or maximum infusion rate of 24 mg / hr or 160 mg bolus reached.  Do not exceed 620 mg / day.  Also, if patient has 
heart failure, consider treatment with dobutamine.  
  
 
CVP 
(recommend)  
  
 
PAOP  
(optional)  
 MAP > 60 mm Hg AND off vasopressors for > 12 hours 
Average urine output < 0.5 
ml/kg/hr  Average urine output > 0.5 
ml/kg/hr  
>8 > 12   
Furosemide* 
Reassess in 1 hour Furosemide* 
Reassess in 4 hours 
4-8 8-12 
Give fluid bolus as fast as possible# 
Reassess in 1 hour  
< 4 < 8 No intervention  
Reassess in 4 hours  
 
CITRIS Protocol Version  9 
 47 APPENDIX E: Time Events Schedule  
 
Assessments  Hour 
0 Q 24 hrs 1st 
7 days or in 
ICU Hour 
48 Hour 
96 Hour 
168 Day 
28 Day 
60 
VS: BP, HR, MAP, RR, Temp., O2 sats, 
CVP, Glasgow Coma Scale  X  X X X   
Body Weight  A  A A    
Suspected or known site of sepsis  A  A A A A A 
I/Os Total and Urine only   X      
Assessment of Acute/Chronic Renal 
Failure and Use of Dialysis  X  X X X X  
Calculate SOFA  Score (post study by 
biostatistician)  X  X X X   
Calculate VE40  Score (post study by 
biostatistician)  A  A A A   
Calculate Oxygenation Index  (post study 
by biostatistician)  A  A A A   
Ventilator Data:  
Tv, FiO2, PEEP, Plateau Pressure, Peak 
Inspiratory Pressure, Mean Airway 
Pressure , Minute Ventilation  A  
A A A   
Labs:  
Arterial Blood Gasses, Na+, K+, BUN, 
Cr, WBC, Hgb, Hct, Platelets, PT/INR  X  
X X X   
Bilirubin Total  X  X X X   
Vasopressors or Inotropes: 
Epi, Nor -epi, Phenylephrine, 
Vasopressin , Dopamine  A  
A A A   
Concomitant Medications:  
Methylprednisone, Hydrocortisone  X  X X X   
AE/SAE Assessments  X  X X X   
Blood for Biomarkers  X  X X X   
Ventilator Free Days       X  
All Cause Mortality       X  
ICU Free Days       X  
Hospital Free Days        X 
Glucose Monitoring  I I I I I   
        
 
 
X = Required 
I= As Needed (See Section 3.3.2) 
A=When  available  
  
 
CITRIS Protocol Version  9 
 48 APPENDIX F:  Adverse  Events  
  
Procedures for Reporting Adverse Events 
 
Assuring patient safety is an essential co mponent of this protocol.  Each participating investigator has 
primary responsibility for the safety of the individual participants under his or her care.  The Principal 
Investigator will evaluate all adv erse events.  The Study Coordinator must view patient records for possible 
adverse events throughout the study period.   
AE/SAEs that meet the definition of reportable events (refer to Appendix F Table 1: Anticipated AEs) or as 
determined by the investigator, will be followed from the time of consent through study hour 168 until resolved,  
resolved with sequelae, unresolvable, or death. 
 SAEs will be collected over the same time period as stated above for AEs.   However, any AEs/SAEs assessed 
as related to study participation (e.g. Disease under study) will be recorded from the time of consenting up to 
and including study hour 168, discharge from the hospital, withdrawal, lost to follow up, or death.   
 Events that do not  meet the definition of an AE include: 
• Any clinically significant abnormal laboratory findings or other abnormal safety assessments that are 
associated with the underlying disease, unless judged by the investigator to be more severe than expected for the subject’s condition.
 
• The disease/disorder being studied, or expected progression, signs, or symptoms of the disease/disorder 
being studied, unless more severe than expected for the subject’s condition.  
• Medical or surgical procedure (e.g., endoscopy, appendectomy); the condition that leads to the procedure is an AE.
 
• Situations where an untoward medical occurrence did not occur (social and/or convenience admission to 
a hospital ). 
• Anticipated day- to-day fluctuations of pre- existing disease(s) or condition(s) present or detected at the 
start of the study that do not worsen;  
• "Lack of efficacy" or "failure of expected pharmacological action" would not be reported as an AE or 
SAE.   However, the signs and symptoms and/or clinical sequelae resulting from lack of efficacy will be 
reported if they meet the definition of an AE or SAE.  
 If an event does not meet the definition of an AE per Section 11, then it cannot be an SAE even if serious 
conditions are met (e.g., hospitalization for signs/symptoms of the disease under study, death due to progression 
of disease, etc).  
  
SAE Follow -up language: 
All AEs and SAEs will be followed until resolution, until the condition stabilizes, until the ev ent is otherwise 
explained, or until the subject is lost to follow -up. 
 
CITRIS Protocol Version  9 
 49 The investigator is obligated to perform or arrange for the conduct of supplemental measurements and/or 
evaluations as may be indicated or as requested by the Lead Site to explain as fu lly as possible the nature and/or 
causality of the AE or SAE.   The investigator is obligated to assist.   This may include additional laboratory 
tests or procedures, or consultation with other health care professionals.   If a subject dies during participation in 
the study or during a recognized follow-up period, the investigator will provide the Lead Site with a copy of any 
autopsy reports. 
 New or updated information will be recorded on the SAE report form.  The investigator will submit any 
updated SAE for m to the Lead Site within the designated reporting time frames.  
 Once the investigator determines that an event meets the protocol definition of an SAE, the SAE will be 
reported to the Lead Site within 24 hours .  Any follow-up information on a previously reported SAE will also 
be reported to the Lead Site within 24 hours. 
 The investigator will always provide an assessment of causality at the time of the initial report as described in 
Section 11. 
 The primary mechanism for reporting SAEs to the Lead Site will be through REDCap and facsimile with an 
accompanying email.  If the electronic system is unavailable for greater than 24 hours, the site will fax and 
email .  Then the site will enter the serious adverse event data into REDCap as soon as it becomes available.  
 After the study is completed at a given site, REDCap will be taken off -line to prevent the entry of new data or 
changes to existing data.  If a site receives a report of a new SAE from a study participant or receives updated data on a previously reported SAE after REDCap has been taken off- line, the site can report this information on 
a paper SAE form via email.  
 Facsimile transmission of the SAE form is the preferred method to transmit this information to the Lead Site 
for SAE receipt.   In rare circ umstances and in the absence of facsimile equipment, notification by telephone is 
acceptable, with a copy of the SAE data collection tool sent by overnight mail.  Initial notification via the telephone does not replace the need for the investigator to comp lete and sign the SAE data collection tool within 
the designated reporting time frames. 
 
1. Serious, Expected, AND Study- Related Adverse Events : adverse events occurring from the time of 
informed consent through study hour 168 or until discharged from the hos pital, withdrawal from the 
study, or death will not be considered ‘reportable’ Adverse Events (AE)/Serious Adverse Events 
(SAE) unless the Investigator has a reasonable doubt regarding the relatedness of the event to the investigational product (refer to T able: Anticipated AE/SAEs for the SEPSIS ALI Study Population).  
 
2.  Serious, U nexpected, AND  Study- Related   Adverse Events:  Investigat ors will repor t all serious,  
unexpected, AND  study- related adver se events from the time of informed consent through study hour 
168, to the Clinical Coordinating Center within 24 hours by em ail.  The local Institutional Review 
Board m ust also be notified in a timely manner.  The investigator will th en submit a det ailed written 
report to  the Clinical Coo rdinating Center and the local Instit utional Revi ew Board no late r than  5 
calendar days aft er the investi gator discovers the event.  
 
3.  Definitions of Adverse Events 
 
CITRIS Protocol Version  9 
 50 a.  A serious adverse event is any event that is fatal or im mediately life threatening, is per manently 
disabling, or severely incapacitating, or requires or prolongs inpatient hospitalization.  
Important m edical events that may not result in death, be life threatening, or require 
hospitalization  may be considered serious adverse events when, based upon appropriate 
medical judg ment, they m ay jeopardize the patient or subject and may require me dical or 
surgical interven tion to p revent one of the outcom es listed above. Life-threatening m eans that 
the pa tient was, in th e view of  the investigat or, at im mediate risk of deat h from  the reaction as 
it occurred. This definition does not include a reaction that, had it occurred in a m ore serious 
form, mi ght have caused dea th.  Assessment of the cause of the event has no bearing on the 
assessment of the ev ent’s sev erity. 
b.  An unexpected event is any experience not identified by the type, severity, or frequency in 
the current study protocol or an event that is unexpected in the course of treat ment for ALI 
or ARDS.  
c.  Adverse events will be considered to  be study- related if the event follows  a reasonable 
temporal sequence from a study procedure and could readily have been produced by the 
study procedure. 
d.  Organ failures or death related to ALI or ARDS or the patient’s underlying condition that are 
systematically captured by the protocol should not be reported as advers e events unless they 
are co nsidered to b e study related . 
 
4.   Assigning Causality 
a.  The investigator is obligated to assess the relationship between investigational product and the occurrence of each AE/SAE.  A "reasonable possibility" is meant to convey that there are facts/evidence or arguments to suggest a causal relationship, rather than a relationship cannot 
be ruled out.  The investigator will use clinical judgment to determine the relationship.  Alternative causes, such as natural history of the underlying diseases, concomitant therapy, other risk factors, and the sequential relati onship of the event to the investigational product 
will be considered and investigated.  The investigator will also consult the Investigator 
Brochure (IB) and/or Product Information, for marketed products, in the determination of 
his/her assessment.  
b.  There  may be situations when an SAE has occurred and the investigator has minimal 
information to include in the initial report to VCU.  However, it is very important that the 
investigator always make an assessment of causality for every event prior to the initi al 
transmission of the SAE data to VCU.   The investigator may change his/her opinion of 
causality in light of follow-up information, amending the SAE report form.   
• Unrelated:  
o Event occurred before dosing;  
o Event or concomitant illness due to factors other than drug or study procedure; 
• Possibly:  
o Reasonable sequential relationship with study procedure or drug treatment;  
o Event could be explained by patient’s clinical state or other factors  
• Probably:  
o Reasonable sequential relationship with study procedure or drug treatment;  
o Likely to be a known reaction to study agent or chemical group, or predicted by known pharmacology;  
o Event cannot easily be explained by patient’s clinical state or other factors.  
• Definitely:  
o Distinct sequential relationship with s tudy procedure or drug treatment;  
 
CITRIS Protocol Version  9 
 51 o Known reaction to study agent or chemical group, or predicted by known 
pharmacology;  
o Event cannot be explained by patient’s clinical state or other factors.  
 
 
ANTICIPATED AE/SAEs for the SEPSIS ALI Study Population 
The following is a list of anticipated Diseases/Illnesses associated with the SEPSIS ALI study population and are expected 
to occur in the study population, independent of investigation product exposure; will be captured as part of the study 
inclusion proc esses and/or study assessments and as such will not be considered ‘reportable’ Adverse Events (AE)/Serious 
Adverse Events (SAE) unless the Investigator has a reasonable doubt regarding the relatedness of the event to the investigational product, from the time of informed consent through Study hour 168 or until discharged from the hospital, 
withdrawn from the study or death.  
AE/SAEs that meet the definition of reportable events or as determined by the investigator, will be followed from the time of consent through study hour 168 until resolved, resolved with sequelae or considered unresolvable. 
NOTE: this list is meant to be as comprehensive as possible for expected events for the Disease under study and may not include all events.  The Investigator responsi bilities for reporting of AE/SAEs still apply, regardless of the table below 
and should be reported if the Investigator has a reasonable doubt regarding the relatedness of the event to the investigational product.  
Table 1:  
Expected Disease(s) Under Study  Associated Symptoms and Labs  
Infection  
 (e.g., thorax, urinary tract, abdomen, skin, sinuses, bacterial meningitis, central 
venous catheters, and central nervous system, see Appendix A) 
 
** Use of antibiotics at ti me of consent (provided the antibi otics are not for 
prophylaxis) is considered evidence of suspected infection. Examples of  
prophylactic antibiotics include: pre -surgical incision, antibiotic for the 
preve ntion of pneum ocystis jiroveci (aka carinii), herpes si mplex, 
cytomegalovi rus, and lat ent mycobacterial disease.  
Acute Lung Injury (ALI)  Fever:   >38ºC (any route) or hypothermia: <36ºC (core temp only),  
Tachycardia:  heart rate > 90 beats/min or receiving medications that slow heart 
rate or paced rhythm,  
Leukocytosis:   >12,000 WBC/µL or leukopenia:  <4,000 WBC/µL or >10% 
band forms.   
Respiratory rate > 20 breaths per minute or  
PaCO2  < 32 or invasive mechanical ventilation.  
Adult Respiratory Distress 
Syndrome (ARDS)  Lung injury of acute onset , within 1 week of an apparent clinical insult  and 
with progression of respiratory symptoms;  
Bilateral opacities on chest imaging not explained by other pulmonary 
pathology (e.g. pleural effusions, lung collapse, or nodules);  
Respiratory failure not explained by heart failure or volume overload;  
Decreased arterial PaO2/FiO2 ratio  ≤ 300 mm Hg;  
Minimum PEEP  of 5 cmH 2O  
Systemic Inflammatory 
Responses (SIRS)  Fever  > 38°C (any route) or hypothermia: < 36 °C (core temp. only)  
 
CITRIS Protocol Version  9 
 52 Tachycardia : heart rate >  90 beats/min or receiving medications that slow heart 
rate or paced rhythm  
Respiratory Rate > 20 breaths per minute or PaC02 < 32 or invasive 
mechanical ventilation  
Leukocytosis : > 12,000 WBC /µL or leukopenia:  <4,000 WBC/µL or >10% 
band forms  
 
Sepsis associated  System Organ 
Failure (SOF) 
The current trial will be enrolling patients with sepsis associated  acute 
lung injury. We therefore expect 
that many of these patients will 
have some degree of organ dysfunction.  
  Sepsis associated  hypotension  (systolic blood pressure (SBP) < 90 mm Hg or 
an SBP decrease > 40 mm Hg unexplained by other causes or use of vasopressors for blood pressure support (epinephrine, norepinephrine, dopamine =/> 5mcg, phenylephrine, vasopressin); 
Arterial hypoxemia  (PaO 2/FiO 2 < 300) or supplemental O2 > 6LPM.  
Lactate  > upper limits of normal laboratory results  
Urine output  < 0.5 ml/kg/hour for > two hours despite adequate fluid 
resuscitation  
Platelet count < 100,000 per mcL  
Coagulopathy (INR > 1.5) Bilirubin > 2 mg/dL  
Glasgo w Coma Scale  < 11 or a positive CAM ICU score  
Biomarkers of Inflammation, 
Vascular Injury and Alveolar 
epithelial injury  Increases in C -reactive protein   (CRP), procalcitonin (PCT), thrombomodulin 
(TM) alveolar epithelial injury (Receptor for Advanced Gl ycation Products)  
Lactic Acidosis  Patients with sepsis are at high risk of metabolic acidosis (including lactic 
acidosis). To prevent the possibility of metabolic acidosis due to drug administration, the study drug is formulated to a neutral pH of 7.4. Therefore, we 
do not anticipate the need for additional monitoring of acid/base balance beyond standard -of-care provided at each institution. Any observed abnormalities will be 
evaluated according to standard -of-care practice and documented in the research  
record.  
Use of Dialysis  In the presence of Acute or Chronic renal failure.  
Septic Shock  Fluid  manage ment during shock will not be pre scribed per study protocol. In 
subjects who are not in shock, a conserv ative fluid managem ent approach will be 
administered, if possible .  (refer to Appendix D, Table 5).  
Use of Ventilator  As per protocol (refer to Section 5.5 and Appendix C)  
Plasma Ascorbate levels  Septic patients exhibit subnormal plasma ascorbate levels. Phase I studies 
performed at Virginia Commonwealth University (VCU) show mean ascorbate levels of 17.5 µM (normal human ascorbate levels 60 to 70 µM).  The day 2 – 7 
plasma ascorbate levels are expected to be bet ween 500 to 1000 µM.  
Death  Organ failures or death related to ALI  or ARDS or the patient’s underlying 
condition that are syste matically captured by the protocol should not be reported 
as adver se events unless they are co nsidered to be study related. (refer to 
Appendix F).  
NOTE: All AE/SAEs considered “Reportable ” will be captured on the adverse event log  and reported to the 
sponsor . 
 
 
  
 
CITRIS Protocol Version  9 
 53 APPENDIX G: Modified SOFA Score Calculator  
 
Value  0 1 2 3 4 Score  
Respiratory  
  
PaO 2/FiO 2 >400  ≤400  ≤300  ≤200  
with  
respiratory  
support  ≤100  
with  
respiratory  
support    
Coagulation  
  
Platelets  >150  ≤150  ≤100  ≤50 ≤20   
GI 
  
T Bilirubin  <1.2 1.2-1.9 2.0-5.9 6.0-11.9 ≥12   
Cardio - 
Vascular 
  No 
Hypo- 
tension  MAP  
<70 Dopa ≤5  
PE <100  Dopa > 5  
Epi ≤ 0.1  
NE ≤ 0.1 
PE 100-
300 
  Dopa>15  
Epi>0.1 
NE>0.1 
PE>300 
VP>0.01   
Neuro  
  
GCS  15 13-14 10-12 6-9 <6   
Serum  
Creatinine  
  
-OR- 
  
Urine  
Output  <1.2 1.2-1.9 2.0-3.4 3.5-4.9 
  
<500cc/ 
day ≥5.0 
  
<200cc/ 
day   
  Total  
 
 
  
1. For patients on supplemental oxygen, add 0.03 to the room air FiO2 (0.21) for each liter of nasal cannula 
oxygen (e.g. 2 liters = FiO 2 of 0.27).  Face mask FiO 2 is whatever amount is being delivered (e.g. 40% 
face mask = FiO 2 of 0.40).  For non- rebreather face masks, use FiO 2 of 0.99. 
2. Doses of dopamine (Dopa), epinephrine (Epi), norepinephrine (NE) are in micrograms/kg/min; phenylephrine 
(PE) is micrograms/min; vasopressin (VP) is U/min. Vasopressors must have been administered for at least one 
hour. 
  
 
CITRIS Protocol Version  9 
 54 APPENDIX H: P/F from S/F  Calculator 
 
 
 
To calculate FiO2 for a non -intubated patient:  
 .21+(3.5 x per liter O2) = FiO2  
 
Calculate PO2/FiO2 by finding SpO2 along the top row and calculated FiO2 along the left vertical axis and finding the 
intersection of the two.  
 
SpO2/FiO2 ratio should only be analyzed if the SpO2 is < 97%.  At values of 97% or greater there is no 
longer an interpretable relationship between SpO2/FiO2 and PaO2/FiO2  
  

 
CITRIS Protocol Version  9 
 55 References Cited:  
i Bone RC, Balk RA, Cerra FB, et al, and members of the ACCP/SCCM Consensus Conference: Definitiona for sepsis and 
organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992;101:1644 -1655 and Crit Care Med 
1992;20:846- 874. 
ii Levy  MM, Fink MP, Marshall JC, et al: 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions 
Conference. Crit Care Med 2003;31:1250-1256.  
iii Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: International guidelines for management of 
severe sepsis and septic shock: 2008 [published correction appears in Crit Care Med 2008;36:1394- 1396. Crit Care Med 
2008;36:296- 327. 
iv Dombrovskiy, V. Y.; Martin, A. A.; Sunderram, J.; Paz, H. L. Rapid increase in hospitalization and mortality rates for 
severe sepsis in the United States: a trend analysis from 1993 to 2003. Crit. Care Med. 35:1244– 1250; 2007.  
v Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. 
N Engl J Med 2003; 348:1546– 1554.  
vi Repine JE. Scientific perspectives on adult respiratory distress syndrome. Lancet 1992;339:466– 469. 
vii Baetz D, Shaw J, Kirshenbaum LA. Nuclear factor -kB decoys suppress endotoxin -induced lung injury. Mol Pharmacol 
2005;67:977 –979. 
viii Nishikimi, M., Fukuyama, R., Minoshima, S., Shimizu, N., and Yagi, K. Cloning and chromosomal mapping of the 
human nonfunctional gene for L -gulono -gamma -lactone oxidase, the enzyme for L -ascorbic acid biosynthesis missing in 
man. (1994) J. Biol. Chem. 269, 13685- 8. 
ix Vera JC, Rivas CI, Fischbarg J, and Golde DW. Mammalian facilitative hexose transporters mediate the transport of 
dehydroascorbic acid. (1993) Nature 364, 79-82.  
x Vera JC, Rivas CI, Velasquez FV, Zhang RH, Concha II, and Golde DW. Resolution of the facilitated transp ort of 
dehydroascorbic acid from its intracellular accumulation as ascorbic acid. (1995) J. Biol. Chem. 270, 23706-12.  
xi Levine M, Wang Y, Padayatty SJ, and Morrow J. A new recommended dietary allowance of vitamin C for healthy 
young women. (2001) Proc. Na t. Acad. Sci. U.S.A. 98, 9842 -6. 
xii Wilson JX. Mechanism of action of vitamin C in sepsis: ascorbate modulates redox signaling in endothelium. 
Biofactors. 2009 Jan-Feb;35(1):5- 13. 
xiii Borrelli E, Roux -Lombard P, Grau GE, Girardin E, Ricou B, Dayer J, Suter PM . Plasma concentrations of cytokines, 
their soluble receptors, and antioxidant vitamins can predict the development of multiple organ failure in patients at risk. 
Crit. Care Med 1996;24:392– 397. [PubMed: 8625625]  
xiv Galley HF, Davies MJ, Webster NR. Ascorbyl radical formation in patients with sepsis: effect of ascorbate loading. 
Free Radic. Biol. Med 1996;20:139 –143. [PubMed: 8903690]  
xv Wilson, J.X.: Regulation of vitamin C transport. Annu. Rev. Nutr., 25, 105– 125, 2005.  
xvi Guaiquil, V. H., J. C. Vera, and D. W. Golde. 2001. Mechanism of vitamin C inhibition of cell death induced by 
oxidative stress in glutathione -depleted HL -60 cells. J. Biol. Chem. 276:40955– 40961.  
xvii Lutsenko, E. A., J. M. Carcamo, and D. W. Golde. 2002. V itamin C prevents DNA mutation induced by oxidative 
stress. J. Biol. Chem. 277:16895– 16899. (Erratum, 277:27576.)  
xviii Levine, M., K. Morita, E. Heldman, and H. B. Pollard. 1985. Ascorbic acid regulation of norepinephrine biosynthesis 
in isolated chromaffin granules from bovine adrenal medulla. J. Biol. Chem. 260:15598– 15603.  
xix Padh, H. 1991. Vitamin C: newer insights into its biochemical functions. Nutr. Rev. 49:65 –70. 
xx Rebouche, C. J. 1991. Ascorbic acid and carnitine biosynthesis. Am. J. Clin. Nutr. 54:1147S –1152S.  
xxi Armour J, Tyml K, Lidington D, Wilson JX. Ascorbate prevents microvascular dysfunction in the skeletal muscle of 
the septic rat. J. Appl. Physiol 2001;90:795 –803. [PubMed: 11181585]  
xxii Kim JY, Lee SM. Vitamins C and E protect hepatic cytochrome P450 dysfunction induced by polymicrobial sepsis. 
Eur. J. Pharmacol 2006;534:202 –209. [PubMed: 16483564]  
xxiii Tyml K, Li F, Wilson JX. Septic impairment of capillary blood flow requires nicotinamide adenine dinucleotide 
phosphate oxidase but not nitric oxide  synthase and is rapidly reversed by ascorbate through an endothelial nitric oxide 
synthase-dependent mechanism. Crit. Care Med 2008;36:2355– 2362. [PubMed: 18596627]  
xxiv Gaut JP, Belaaouaj A, Byun J, Roberts LJ II, Maeda N, Frei B, Heinecke JW. Vitamin C fails to protect amino acids 
and lipids from oxidation during acute inflammation. Free Radic. Biol. Med 2006;40:1494 –1501. [PubMed: 16632110]  
                                                             
 
CITRIS Protocol Version  9 
 56                                                                                                                                                                                                                              
xxv Vissers MC, Gunningham SP, Morrison MJ, Dachs GU, Currie MJ. Modulation of hypoxia-inducible factor -1 alpha in 
cultured primary cells by intracellular ascorbate. Free Radic Biol Med 2007;42:765 -772.  
xxvi Cepinskas G, Wilson JX. Inflammatory response in microvascular endothelium in sepsis: role of oxidants. J Clin 
Biochem Nutr. 2008 May;42(3):175-84.  
xxvii Matthay MA, Zimmerman GA, Esmon C, Bhattacharya J, Coller B, Doerschuk CM, Floros J, Gimbrone MA Jr, 
Hoffman E, Hubmayr RD, et al. Future research directions in acute lung injury: summary of a National Heart, Lung, and 
Blood Institute working group. Am J Respir Crit Care Med 2003;167:1027– 1035.  
xxviii Kabir K, Gelinas JP, Chen M, Chen D, Zhang D, Luo X, Yang JH, Carter D, Rabinovici R. Characterization of a 
murine model of endotoxin -induced acute lung injury. Shock 2002;17:300–303.  
xxix Cohen, J.: The immunopathogenesis of sepsis. Nature, 420, 885 –891, 2002.  
xxx Abraham, E. and Singer, M.: Mechanisms of sepsis-induced organ dysfunction. Crit. Care Med., 35, 2408 –2416, 2007.  
xxxi Abraham, E.: Nuclear factor -kappaB and its role in sepsisassociated organ failure. J. Infect Dis., 187 Suppl. 2, S364– 
369, 2003.  
xxxii Rao, R.M., Yang, L., Garcia -Cardena, G., and Luscinskas, F.W.: Endothelial-dependent mechanisms of leukocyte 
recruitment to the vascular wall. Circ. Res., 101, 234 –247, 2007.  
xxxiii Bernard, G.R., Vincent, J.L., Laterre, P.F., LaRosa, S.P., Dhainaut, J.F., Lopez -Rodriguez, A., Steingrub, J.S., 
Garber,  
G.E., Helterbrand, J.D., Ely, E.W., and Fisher, C.J., Jr.: Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med., 344, 699 –709, 200 1. 
xxxiv Panacek, E.A., Marshall, J.C., Albertson, T.E., Johnson, D.H., Johnson, S., MacArthur, R.D., Miller, M., Barchuk, 
W.T., Fischkoff, S., Kaul, M., Teoh, L., Van Meter, L., Daum, L., Lemeshow, S., Hicklin, G., and Doig, C.: Efficacy and safety of the mon oclonal anti -tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis 
and elevated interleukin -6 levels. Crit. Care Med., 32, 2173 – 2182, 2004.  
xxxv Erickson SE, Martin GS, Davis JL, Matthay MA, Eisner MD. Recent trends in acu te lung injury mortality: 1996-2005. 
Crit Care Med 2009; 37: 1574-1579.  
xxxvi Nathens AB, Neff MJ, Jurkovich GJ, Koltz P, Farver K, Ruzinski JT, Radella F, Garcia I, Maier RV. Randomized, 
prospective trial of antioxidant supplementation in critically ill surgical patients. Ann Surg; 236:814- 822, 2002.  
xxxvii Muhlhofer A, Mrosek S, Schlegel B, Trommer W, Rozario F, Bohles H, Schremmer D, Zoller WG, Biesalski HK. 
High -dose intravenous vitamin C is not associated with an increase of pro -oxidative biomarkers. Euro Journ  Clin 
Nutrition 58:1151- 1158, 2004.  
xxxviii Tanaka H, Matsuda T, Miyagantani Y, Yukioka T, Matsuda H, Shimazaki S. Reduction in reduscitation fluid 
volumes in severely burned patients using ascorbic acid administration, Arch Surg 135:326-331, 2000.  
xxxix Gando S, Kameue T, Nanzaki S, Nakanishi Y. Disseminated Intravascular coagulation is a frequent complication of 
systemic inflammatory response syndrome. Thromb Haemost  75: 224 -228, 1996.  
xl Bastarache JA, Wang L, Wang Z, Albertine KH, Matthay MA, Ware LB. Intra-alveolar tissue factor pathway inhibitor 
is not sufficient to block tissue factor procoagulant activity. Am J Physiol Lung Cell Mol Physiol 294: L874 -881, 2008.  
xli Ferreira FL, Bota DP, Bross A, Mélot C, Vincent JL. Serial evaluation of the SOFA score to predict outcome in 
critically ill patients. JAMA. 2001 Oct 10;286(14):1754-8.  
xlii Nishikimi M, Kukuyama r, Minoshima S, Shimizu N, Yagi K. Cloning and chromosomal mapping of the human 
nonfunctional gene for L -gulono- gamma -lactone oxidase, the enzyme for L -ascorbic acid biosynthesis missing in man. J 
Biol Chem. 1994;269:13685-88.  
xliii Vera JC, Rivas CI, Fischbarg j, Golde DW. Mammalian facilitative hexose transporters mediate the transport of 
dehydroascorbic acid. Nature. 1993;364:79-82.  
xliv Levine M, Wang Y, Padayatty SJ, Morrow J. A new recommended dietary allowance of vitamin C for healthy young 
women. Proc Nat Acad Sci USA. 2001;98:9842 -46. 
xlv Galley HF, Davies MJ, Webster NR. Ascorbyl radical  formation in patients with sepsis: effect of ascorbate loading. 
Free Rad Biol Med 1996;20(1):139-143.  
xlvi Baines M, Shenkin A. Lack of effectiveness of short -term intravenous micronutrient nutrition in restoring plasma 
antioxidant status after surgery. Clin  Nutr. 2002;21(2):145-50.  
xlvii Wu F, Wilson JX, Tyml K. Ascorbate inhibits iNOS expression and preserves vasoconstrictor responsiveness in 
skeletal muscle of septic mice. Am J Physiol Regul Integr Comp Physiol. 2003;285:R50- 56. 
xlviii Armour J, Tyml K, Lidington D , Wilson JX. Ascorbate prevents microvascular dysfunction in the skeletal muscle in 
the septic rat. J Appl Physiol 2001;90:795 -803.  
 
 
CITRIS Protocol Version  9 
 57                                                                                                                                                                                                                              
xlix Han M Pendem s, The SL, Sukumaran DK, Wu F, Wilson JX. Ascorbate protectsendothelial barrier function during 
septic insult : Role of protein phosphatase type 2A. Free Radic Biol Med. 2010;48(1):128-35.  
l Kirsch M, de Groot H. Ascorbate is a potent antioxidant against peroxynitrite-induced oxidation reactions. Evidence that 
ascorbate acts by re-reducing substrate radicals produ ced by peroxinitrite. J Biol Chem 2000;275:16702- 708. 
li Padayatty SJ, Sun H, Wang Y, Riordan HD, Hewitt SM, Katz A, Wesley RA, Levine M. Vitamin C pharmacokinetics: 
Implications for oral and intravenous use. Ann Intern Med. 2004;140:533-537.  
lii Jabour ER, R abil DM, Truwit JD, Rochester DF. Evaluation of a new weaning index based on ventilatory endurance 
and the efficiency of gas exchange. Am Rev Respir Dis. 1991 Sep;144(3 Pt 1):531-7.  
liii Ventil ation with lower tidal volu mes as co mpared with t raditional tidal vo lumes for acute lung injury and the acute 
respiratory distr ess syndro me. The Acute Respiratory Distress Syndro me Network. N Engl J Med 2000; 342:1301-1308  
liv Wiedemann HP, Wheeler AP, Bernard GR, et al. Co mparison of two fluid-m anag ement strategies in acute lung inju ry. 
N Engl J Med 2006; 354:2564-2575  
lv Searle SR. Mixed Liner Models. Biometrics. 1971;27(1):15.  
lviWolfinger R, O’Connell M. Generalized linear mixed models a pseudo -likelihood approach J Stat Comp Sim. 
1993;48(3):233-43.  
lvii Little RJA. A test of issing completely at random for multivariate data with missing values. J Amer Stat Assn. 
1998;83:1198.  
lviii Mühlhöfer A, Mrosek S, Schlegel B, Trommer W, Rozario F, Böhles H, Schremmer D, Zoller WG, Biesalski HK. 
High -dose intravenous vitamin C is not ass ociated with an increase of pro -oxidative biomarkers. Eur J Clin Nutr. 2004 
Aug;58(8):1151-8.  
lix Nathens AB, Neff MJ, Jurkovich GJ, Klotz P, Farver K, Ruzinski JT, Radella F, Garcia I, Maier RV. Randomized, 
prospective trial of antioxidant supplementation i n critically ill surgical patients. Ann Surg. 2002;236(6):814-22.  
lx Hoffer LJ, Levine M, Assouline S, Melnychuk D, Padayatty SJ, Rosadiuk K, Rousseau C, Robitaille L, Miller WH Jr. 
Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. Ann On col. 2008 Nov;19(11):1969-74.  
lxi Biesalski, H. K. (2008). Parenteral ascorbic acid in haemodialysis patients.  Current Opinion in Clinical Nutrition and 
Metabolic Care, (11), 741-746.  
lxii National Bioethics Advisory Com mittee (NBAC). Research Involving Persons  with Ment al Dis orders Th at May Affect 
Decision making Capacity. Rockvill e: U.S. Govern ment Printing Office, 1998  
lxiii Office of Hu man Research Protections (OHRP). Co mpliance Deter mination Letters, 2002  
lxiv Dresser R. Research Involving Persons with  Mental Disabilities: A Review of Policy Issues and Proposals. 
National Bioethics Advisory Com mission. Rockville: U.S. Govern ment Printing Office, 1999; 5 -28 
lxv American College of P hysicians. Cognitiv ely Impaired Su bjects. Ann Int Med 1989;  
111:843-848  
lxvi Jonas E, Dwenger A, Hager A.  In vitro effect of ascorbic acid on neutrophil -endothelial cell interaction.  J Biolumin Chemilumin. 
1993;8(1):15-20.  
lxvii Parker A, Cuddihy SL, Son TG, Vissers MC, Winterbourn CC.  Roles of superoxide and myeloperoxidase in ascorb ate oxidation in 
stimulated neutrophils and H2O2- treated HL60 cells.  Free Radic Biol Med. 2011;51(7):1399- 405.  
lxviii Loke WM, Proudfoot JM, McKinley AJ, Croft KD.  Augmentation of monocyte intracellular ascorbate in vitro protects cells from 
oxidative damage an d inflammatory responses.  Biochem Biophys Res Commun. 2006;345(3):1039- 43. 
lxix Pan JP, Cheng TM, Chou SC, Lai ST  Vitamin C protects against lysophosphatidylcholine -induced expression of monocyte 
chemoattractant protein -1 in cultured human umbilical vein endo thelial cells.  Formos Med Assoc. 2003;102(3):151- 7. 
lxx Raghavan SA, Sharma P, Dikshit M. Role of ascorbic acid in the modulation of inhibition of platelet aggregation by 
polymorphonuclear leukocytes. Thromb Res. 2003 May 1;110(2-3):117-26.  
lxxi Pignatelli P, Sanguigni V, Paola SG, Lo Coco E, Lenti L, Violi F. Vitamin C inhibits platelet expression of CD40 
ligand. Free Radic Biol Med. 2005 Jun 15;38(12):1662-6.  
lxxii Wu F, Schuster DP, Tyml K, Wilson JX.  Ascorbate inhibits NADPH oxidase subunit p47phox expression in microvascular endothelial 
cells.  Free Radic Biol Med. 2007 Jan 1;42(1):124-31.  
lxxiii Woo A, Kim JH, Jeong YJ, Maeng HG, Lee YT, Kang JS, Lee WJ, Hwang YI.  Vitamin C acts indirectly to modulate isotype switching in 
mouse B cells.  Anat Cell Biol. 2010;43(1):25 -35. 
lxxiv Härtel C, Strunk T, Bucsky P, Schultz C.  Effects of vitamin C on intracytoplasmic cytokine production in human whole blood 
monocytes and lymphocytes.  Cytokine. 2000;27(4- 5):101-6 
 
 
 
 
CITRIS Protocol Version  9 
 58                                                                                                                                                                                                                              
 
 
 
 
 
 
 
Härtel C, Strunk T, Bucsky P, Schultz C.  
lxxv Muellner MK, Schreier SM, Schmidbauer B, Moser M, Quehenberger P, Kapiotis S, Goldenberg H, Laggner H.  Vitamin C inhibits 
NO-induced stabilization of HIF- 1alpha in HUVECs.  Free Radic Res. 2010;44(7):783-91.  
lxxvi Qiao H, Li L, Qu ZC, May JM  Cobalt-induced oxi dant stress in cultured endothelial cells: prevention by ascorbate in relation to HIF-
1alpha.  Biofactors. 2009;35(3):306- 13. 
lxxvii Fisher BJ, Seropian IM, Kraskauskas D, Thakkar JN, Voelkel NF, Fowler AA 3rd, Natarajan R.  Ascorbic acid attenuates Crit Care 
Med . 2011 Jun;39(6):1454- 60. 
lxxviii Zhou G, Kamenos GC, Pendem S, Wilson JX, Wu F.  Ascorbate protects against vascular leakage in cecal ligation and puncture -
induced septic peritonitis.  Am J Physiol Regul Integr Comp Physiol. 2011.  
lxxix Tyml K, Li F, Wilson JX.  Septi c impairment of capillary blood flow requires nicotinamide adenine dinucleotide phosphate oxidase 
but not nitric oxide synthase and is rapidly reversed by ascorbate through an endothelial nitric oxide synthase -dependent 
mechanism.  Crit Care Med. 2008;36(8) :2355 -62. 
lxxx Wu F, Wilson JX, Tyml K  Ascorbate inhibits iNOS expression and preserves vasoconstrictor responsiveness in skeletal muscle of 
septic mice.  Am J Physiol Regul Integr Comp Physiol. 2003;285(1):R50- 6. 
lxxxi Wu F, Tyml K, Wilson JX.  Ascorbate inhibits iNOS expression in endotoxin - and IFN gamma -stimulated rat skeletal muscle 
endothelial cells.  FEBS Lett. 2002;520(3):122 -6. 
lxxxii Park JK, Ki MR, Lee HR, Hong IH, Ji AR, Ishigami A, Park SI, Kim JM, Chung HY, Yoo SE, Jeong KS.  Vitamin C deficiency attenuates 
liver fibrosis by way of up -regulated peroxisome proliferator -activated receptor -gamma expression in senescence marker protein 30 
knockout mice.  Hepatology. 2010;51(5):1766-77.  
lxxxiii Stirrat A, Nelli S, Dowell FJ, Martin W.  Flow- induced enhancement of vasoconstriction and blockade of endothelium -derived 
hyperpolarizing factor (EDHF) by ascorbate in the rat mesentery.  Br J Pharmacol. 2008;153(6):1162 -8. 
lxxxiv Stirrat A, Nelli S, McGuckin A, Ho VW, Wilson WS, Martin W.  Ascorbate elevates perfusion pressure in the bov ine extraocular 
long posterior ciliary artery: role of endothelium -derived hyperpolarizing factor (EDHF). Br  J Pharmacol. 2006;534(1- 3):152- 8. 
lxxxv Rivas CI, Zúñiga FA, Salas -Burgos A, Mardones L, Ormazabal V, Vera JC.  Vitamin C transporters. J Physiol Bioche m. 
2008;64(4):357 -75. 
lxxxvi Hu S, Che JW, DU Y, Bao CM.  [Observation on the effect of vitamin C in alleviating peroxidative damage in gut of dogs during 
enteral fluid resuscitation of severe burn shock]. Zhonghua Shao Shang Za Zhi. 2009;25(6):451- 3. 
lxxxvii Hamilton  GJ, Van PY, Differding JA, Kremenevskiy IV, Spoerke NJ, Sambasivan C, Watters JM, Schreiber MA.  Lyophilized plasma 
with ascorbic acid decreases inflammation in hemorrhagic shock.  J Trauma. 2011;71(2):292 -7; discussion 297 -8. 
lxxxviii Li SH, Ryu JH, Park SE, Cho YS, Park JW, Lee WJ, Chun YS Vitamin C supplementation prevents testosterone -induced hyperplasia 
of rat prostate by down -regulating HIF -1alpha. J Nutr Biochem. 2010;21(9):801 -8. 
lxxxix Buehler PW, D'Agnillo F, Hoffman V, Alayash AI.  Effects of endogenous ascorbate on oxidation, oxygenation, and toxicokinetics 
of cell -free modified hemoglobin after exchange transfusion in rat and guinea pig.  J Pharmacol Exp Ther. 2007;323(1):49- 60. 
xc Buehler PW, D'Agnillo F, Hoffman V, Alayash AI.  Effects of endogenous ascorbate on oxidation, oxygenation, and toxicokinetics of 
cell-free modified hemoglobin after exchange transfusion in rat and guinea pig.  J Pharmacol Exp Ther. 2007;323(1):49-60..  
xci Woollard KJ, Loryman CJ, Meredith E, Bevan R, Shaw JA, Lunec J, Griffiths HR.  Effec ts of oral vitamin C on monocyte: endothelial 
cell adhesion in healthy subjects.  Biochem Biophys Res Commun. 2002 Jun 28;294(5):1161- 8. 
xcii Tarng DC, Liu TY, Huang TP.  Protective effect of vitamin C on 8 -hydroxy- 2'-deoxyguanosine level in peripheral blood lymphocytes 
of chronic hemodialysis patients.  Kidney Int. 2004 Aug;66(2):820- 31. 
xciii Crecelius AR, Kirby BS, Voyles WF, Dinenno FA.  Nitric oxide, but not vasodilating prostaglandins, contributes to the improvement 
of exercise hyperemia via ascorbic acid in hea lthy older adults.  Am J Physiol Heart Circ Physiol. 2010;299(5):H1633- 41. 
xciv Basili S, Tanzilli G, Mangieri E, Raparelli V, Di Santo S, Pignatelli P, Violi F.  Intravenous ascorbic acid infusion improves myocardial 
perfusion grade during elective percutaneous coronary intervention: relationship with oxidative stress markers.  JACC Cardiovasc 
Interv. 2010;3(2):221- 9. 
xcv Zhang K, Liu L, Cheng X, Dong J, Geng Q, Zuo L  Low levels of vitamin C in dialysis patients is associated with decreased prealbumin 
and increased C -reactive protein. BMC Nephrol. 2011;12:18.  
xcvi Kubota Y, Moriyama Y, Yamagishi K, Tanigawa T, Noda H, Yokota K, Harada M, Inagawa M, Oshima M, Sato S, Iso H.  Serum 
vitamin C concentration and hs -CRP level in middle -aged Japanese men and women.  Atherosclerosis. 2010;208(2):496- 500.  
 
 
CITRIS Protocol Version  9 
 59                                                                                                                                                                                                                              
xcvii Mah E, Matos MD, Kawiecki D, Ballard K, Guo Y, Volek JS, Bruno RS.  Vitamin C status is related to proinflammatory responses and 
impaired vascular endothelial function in healthy, college -aged lean and obese men.  J Am Diet Assoc. 2011;111(5):737- 43. 
xcviii Castillo R, Rodrigo R, Perez F, Cereceda M, Asenjo R, Zamorano J, Navarrete R, Villalabeitia E, Sanz J, Baeza C, Aguayo R.  
Antioxidant therapy reduces oxidative and inflammatory tissue damage in patients subjected to car diac surgery with extracorporeal 
circulation.  Basic Clin Pharmacol Toxicol. 2011;108(4):256- 62. 
xcix Finkelstein FO, Juergensen P, Wang S, Santacroce S, Levine M, Kotanko P, Levin NW, Handelman GJ.  Hemoglobin and plasma 
vitamin C levels in patients on peritoneal dialysis.  Perit Dial Int. 2011;31(1):74- 9. 
c Nathens AB, Neff MJ, Jurkovich GJ, Klotz P, Farver K, Ruzinski JT, Radella F, Garcia I, Maier RV.  Randomized, prospective trial of 
antioxidant supplementation in critically ill surgical patients.  Ann Surg. 2002;236(6):814 -22. 
ci The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional 
tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome 
Network.  2000; 342:1301 -1308  
cii Brower RG, Lanken PN, MacIntyre N, et al. Higher versus lower positive end -expiratory pressures in patients with the 
acute respiratory distress syndrome. N Engl J Med 2004;  
351:327-336  